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A B S T R A C T   
The absorption of oral drugs is frequently plagued by significant variability with potentially serious therapeutic 
consequences. The source of variability can be traced back to interindividual variability in physiology, differ-
ences in special populations (age- and disease-dependent), drug and formulation properties, or food-drug in-
teractions. Clinical evidence for the impact of some of these factors on drug pharmacokinetic variability is 
mounting: e.g. gastric pH and emptying time, small intestinal fluid properties, differences in pediatrics and the 
elderly, and surgical changes in gastrointestinal anatomy. However, the link of colonic factors variability (transit 
time, fluid composition, microbiome), sex differences (male vs. female) and gut-related diseases (chronic con-
stipation, anorexia and cachexia) to drug absorption variability has not been firmly established yet. At the same 
time, a way to decrease oral drug pharmacokinetic variability is provided by the pharmaceutical industry: 
clinical evidence suggests that formulation approaches employed during drug development can decrease the 
variability in oral exposure. This review outlines the main drivers of oral drug exposure variability and potential 
approaches to overcome them, while highlighting existing knowledge gaps and guiding future studies in this 
area.   
1. Introduction 
The oral intake of drugs remains the preferred administration route 
because of its non-invasive character and convenience for the patient, 
which increases drug regimen compliance. However, ensuring sufficient 
and predictable systemic drug exposure when developing oral drug 
products is not straightforward (Basavaraj and Betageri, 2014; Kor-
stanje, 2003; Li et al., 2016): issues with bioavailability and pharma-
cokinetics (PK) are among the top 3 reasons for attrition of oral 
small-molecule new drug candidates. In particular, the effectiveness of 
oral drug products in clinical practice can be plagued by significant 
variability in drug exposure with serious therapeutic consequences 
(Pasipanodya et al., 2012). 
It is logical to expect that the factors, which control drug absorption 
and PK, are also responsible for the variability of drug exposure 
observed in the clinic. Hence, the impact of physiological differences (in 
special populations and gastrointestinal tract (GIT) regions), drug and 
formulation properties, and food-drug interactions on drug absorption 
was recognized and described by the European Network on Under-
standing Gastrointestinal Absorption-related Processes (UNGAP)(Boyd 
et al., 2019; Koziolek et al., 2019; Stillhart et al., 2020; Vertzoni et al., 
2019). Considering the complexity and the lack of awareness about 
variability, the current review expands beyond the state-of-the-art to 
provide a focused description and analysis of the subject. Particular 
attention was paid to examples, which demonstrate the link between 
GIT variability and drug absorption/PK, in both fasted and post-prandial 
conditions. 
All anatomical, physiological and pharmaceutical factors that were 
considered as a source of variability in the current paper are listed in 
Table 1. 
The drug transit times (gastric emptying time (GET), intestinal 
transit time) and fluid volumes (including intestinal fluid pockets) in the 
GIT have been identified as considerable sources of variability and are 
the first factors discussed in the current review. The body of literature, 
which describes the compositional and physicochemical (e.g. pH and 
buffer capacity (buffer capacity)) variability of human gastric and in-
testinal fluids, will also be discussed from the angle of their contribution 
to oral absorption variability. Further down the GIT, the impact of the 
gut microbiota and bacterial drug degradation on variability will be 
addressed. The specific effect of formulation-related parameters are 
described in a separate section. Next, a number of additional factors, 
which are usually disregarded, but can play a huge role in the context of 
variability will be examined. These include the influence of age (pedi-
atrics, geriatrics), sex and disease-specific differences. Finally, an in-
dustry perspective on how drug product development takes into account 
the aforementioned challenges and succeeds to limit variability and 
provide drug exposure at therapeutic levels, will be presented. 
In various sections, results obtained from different studies are re-
ported. In order to compare the study results, the best option would be to 
perform a meta-analysis of the available data. However, as most results 
available in the literature are based on small scale explorative clinical 
studies, a statistical comparison is usually not justified. In addition, 
differences in the experimental protocols and instrumentation used to 
gather the data would undermine any attempts at such analysis. 
Therefore, results are reported in a descriptive way. 
Furthermore, the impact of methodology, clinical study design and 
statistics on the measurement and quantification of variability is an issue 
on its own (Augustijns et al., 2020; Evans, 2010; Pocock et al., 2015) and 
will not be addressed in the current paper. The effect of drug absorption 
variability on clinical performance and therapeutic outcome is also not 
in the scope of the current review. 
2. Physiological inter- and intraindividual variability in the 
fasted and fed state 
2.1. Gastric conditions 
This section focuses on the variability of data in healthy fasted and 
fed state adults. Fasted state is defined as an overnight fast, followed by a 
glass of water in the morning. The fed state data reported was generated 
by using the standard U.S. Food and drug administration agency (FDA) 
meal: a high-calorie (900–1000 kcal) breakfast with approximately 150, 
250, and 500–600 calories originating from protein, carbohydrate and 
fat, respectively (EMA 2010; FDA 2002). 
2.1.1. pH and buffer capacity 
In the fasted state, median gastric pH values 10–20 min and 
30–40 min after a glass of water have been reported to be 1.7–3.3 and 
1.6–2.7, respectively (Kalantzi et al., 2006; Koziolek et al., 2014; Petrakis 
et al., 2015). The resistance of gastric fluids to increase with one pH unit 
when titrating with NaOH (buffer capacity) varies with gastric pH and 
becomes close to zero in adults treated with famotidine (Figure 1). 
Oncology drugs constitute an important example of the impact of 
gastric pH in PK variability, as about half of oral cancer therapies are 
weak bases and display solubility-limited dissolution properties (Sme-
lick et al., 2013). The implications of chronic use of PPI inhibitors on oral 
drug absorption are considerable and are examined in detail in section 
4.3.3. 
In the fed state, the median pH values reported in literature at 30 min 
and 60 min after administration of the standard meal are around 3.5 
(Dressman et al., 1990; Koziolek et al., 2015b) and 3 (Dressman et al., 
1990; Koziolek et al., 2014; Pentafragka et al., 2020b), respectively. pH 
values return to baseline levels (median pH value lower than 2) at about 
3 hours after the meal (Dressman et al., 1990; Koziolek et al., 2014). 
Interestingly, intraindividual variability in pH values is low. The 
average difference in pH values at specific time points during the first 
three hours after meal administration in a given individual ranges from 
-0.3 to 0.9 pH units (Pentafragka et al., 2020b). During the first four 
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hours after initiation of meal administration, the average buffer capacity 
of antral contents is about 20 mmol/L/ΔpH (Pentafragka et al., 2020b). 
In line with pH data, the average difference in buffer capacity values 
during the first three hours after meal administration in a given indi-
vidual is low and ranges from -3.4% to 15% (Pentafragka et al., 2020b). 
2.1.2. Volumes 
Based on various magnetic resonance imaging (MRI) studies per-
formed after at least 8 h of fasting, the volume of gastric contents is 
typically below 50 mL (Koziolek et al., 2016). Interestingly, interindi-
vidual and intraindividual variability is comparable, suggesting that the 
variability within the studies is mainly resulting from intraindividual 
day-to-day variations (Grimm et al., 2018a). On the other hand, direct 
aspiration of gastric contents in the fasted state indicates very limited 
resting gastric volumes (mean and median values less than 10 mL, 
n = 15) (Vertzoni et al., 2020a). 
In the fed state, intragastric volumes are similar or slightly higher 
than the volume of the standard meal (slightly more than 500 mL) for 
more than two hours after administration of the standard meal (Koziolek 
et al., 2014; Pentafragka et al., 2020b), implying that gastric emptying of 
meal contents is balanced by intragastric secretions. Inter-individual 
variability in volumes 15 minutes after intake of the standard meal is 
low (579.6 ± 38.1 mL, n=12)(Koziolek et al., 2014). 
2.1.3. Viscosity and osmolality 
Both under fasting and under fed state conditions the gastric contents 
show pseudoplastic behavior, i.e. viscosity decreases with increasing 
shear rate. Especially after the standard meal, intragastric viscosity is 
highly variable (Pentafragka et al., 2020a). On average, the viscosity of 
gastric contents in the fasted state at 37 ◦C (1.4–6.4 mPa•s at a shear rate 
of 100 s− 1 (Pedersen et al., 2013)) is 80–800 times lower than the vis-
cosity at a shear rate of 100 s− 1, after the standard meal (Pentafragka 
et al., 2020a). Similar observations have been made at shear rates of 50 
and 200s− 1. A non-caloric hydroxy-propyl-methyl-cellulose aqueous 
meal, with a viscosity similar to intraluminal fed state values (Penta-
fragka et al. 2020b), has been shown to significantly decrease indinavir 
plasma concentrations after administration of Crixivan® capsules, as 
compared to the fasted state administration with an equal volume of 
water (Carver et al., 1999). 
In the fasted state, contents are highly hypoosmotic (Pentafragka et al., 
2019). After the standard meal, osmolality increases to reach iso-osmotic 
levels (Pentafragka et al., 2020a). The potential impact of such difference 
on gastric emptying rates in humans has not been investigated, however, 
hyperosmolarity delays the gastric emptying of liquid caloric meals 
(Paraskevopoulos et al., 1988; Vermeulen et al., 2011). 
2.1.4. Composition 
In the fasted state, bile salt levels are highly variable and concen-
trations are up to 0.15 mM on average (Pentafragka et al., 2019). In the 
fed state, no data after the standard meal have been reported. 
There are no data on lipid levels in the fasted state (Pentafragka et al., 
2019). After the standard meal, lipid concentrations are highly variable 
both between and within subjects (Pentafragka et al., 2020a). One 
reason may be the non-homogenous distribution of lipid components in 
the gastric contents (Koziolek et al., 2014). On average, triacylglycerides 
(TAG), diacylglycerides (DAG), free fatty acids (FFA) and phosphati-
dylcholine (PC) are comparatively the most abundant lipids (Penta-
fragka et al., 2020a). It has been shown that modelling of intragastric 
lipolysis is necessary for simulating felodipine release from extended 
release tablets in the fed stomach (Diakidou et al., 2009a), whereas 
simulation of colloidal species seems to be key for the prediction of 
intragastric apparent solubility of lipophilic molecules in the fed stom-
ach (Diakidou et al., 2009b). 
2.1.5. Gastric emptying of drugs 
Fasted state. Gastric emptying of aqueous drug solutions administered in 
a total volume of about a glass of water (200–250 mL) is an apparent 
first-order process (Grimm et al., 2018b; Mudie et al., 2014). Interindi-
vidual and intraindividual variability of the process is comparable, 
suggesting that the variability within the studies was mainly resulting 
from intraindividual day-to-day variations (Grimm et al., 2018a). Based 
on published data, gastric emptying half-life can be estimated to be 
11 min (85% of initial gastric volume is emptied after 30 min (Grimm 
et al., 2018a)) or slightly longer (15 min (Kourentas et al., 2016b)). A 
slightly increased half-life of gastric emptying may be expected in case 
the administered aqueous solution is acidic or with increased caloric 
value (Cooke and Hunt, 1970). 
Drug suspensions in aqueous media seem to empty with water unless 
intragastric dispersion of the particles is problematic. In the latter case, 
gastric emptying can be delayed substantially (Kourentas et al., 2016a). 
Disintegrating solid dosage forms typically empty from stomach after 
disintegration. Rupture times of less than 10 min have been reported for 
hard gelatine capsules (Digenis et al., 2000). On average, disintegration 
times in the stomach after administration of the dosage form with a glass 
of water have been reported to be 10–20 min for tablets (Kelly et al. 
2003) and little less than 30 min for the immediate release (IR) layer of a 
modified release product (Weitschies et al., 2008). It should be noted, 
however, that disintegration times depend to a significant extent not 
only on physiological conditions (liquid volumes, mixing), but also on 
the type of formulation and excipients used (Quodbach and Kleine-
budde, 2016). As most of the water will be emptied until complete 
disintegration of tablets, emptying of disintegrating particles will be 
affected by the inter-digestive motility pattern and the density of the 
disintegrated particles. One of the first relevant studies in adults was 
performed by Aoyagi et al (Aoyagi et al., 1992). After an overnight fast, 
three adults received together with 200 mL water at two different oc-
casions on a crossover basis: (A) 5 spherical enteric coated tablets of 
barium sulfate and (B) 50 cylindrical granules of barium sulfate coated 
with ethylcellulose. No food was consumed until 4 h after dosing. The 
number of tablets and granules remaining in the stomach were deter-
mined by periodic roentgenography. Data after administration of the 
tablets in one of the adults indicated 80 % gastric retention at 2 h. The 
same volunteer retained about 90 % of the granules in the stomach 1.5 h 
after dosing, with the granules appearing to lie along the gastric wall, as 
if trapped in the mucus layer. Authors concluded that the strength of the 
Table 1 
Anatomical, physiological and pharmaceutical factors discussed in the frame of oral absorption variability in the current paper.  
Stomach Small intestine Colon Special populations Pharmaceutical factors 
Gastric pH Small intestinal transit time Colonic transit times Pediatrics Drug properties 
Volume of gastric fluids Intestinal fluid volume Colonic luminal composition Geriatrics Formulation effects 
Viscosity and osmolality Viscosity and osmolality Microbiome Sex differences Fasted vs. fed state 
Composition of gastric fluids Intestinal fluid composition  Post-bariatric surgery changes  
Gastric emptying time Intestinal pH  Surgical resection   
Epithelial permeability  Chronic constipation   
Absorption into blood and lymph  Small intestinal motility disorder   
Enterohepatic circulation  Patients on proton pump inhibitors     
Anorexia and cachexia patients   
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phasic contractions in addition to the time of occurrence of the phasic 
gastric contraction seemed to increase the variability of gastric emptying 
of non-digestible solids, at least of those with somewhat increased 
density. 
Non-disintegrating dosage form (e.g. enteric coated or certain 
extended release tablets) are emptied from the stomach mainly during 
Phase III of the inter-digestive migrating motor complex (IMMC), i.e. 
their bolus emptying is difficult to manage, and can remain in the 
stomach up to 2 h or even longer (Koziolek et al., 2016). A significant 
consequence of this variability relates to the fact that safe and effica-
cious gastroretentive dosage forms remain an unmet goal, especially 
under fasting conditions, although they are considered as promising 
drug delivery systems (Lopes et al., 2016). 
Fed state. Aqueous drug solutions administered after the standard meal 
are typically emptied as if they were administered in the fasted state 
(Grimm et al., 2017). For IR tablets or IR layers of modified release 
tablets, time for complete disintegration in the human stomach after a 
high-caloric, high-fat meal has been reported to range on average from 
slightly more than 10 min to about one hour (Kelly et al., 2003; Weits-
chies et al., 2008; Rubbens et al., 2019). For hard gelatine capsules, 
rupture time in the fed state is typically slightly longer than 10 min 
(Digenis et al., 2000). After disintegration of the dosage form, gastric 
emptying half-lifes of Biopharmaceutics classification system (BCS) class 
1 and class 2 drugs administered after the standard meal have been 
estimated to be around 40 min (Pentafragka et al., 2020b). Data on 
disintegration times and subsequent gastric emptying half-lifes are in 
line with earlier data: the half GET of paracetamol administered as 
Panadol IR tablets after the standard meal varies from 77 to 106 min 
(Kelly et al., 2003) with obvious consequences on the variability in the 
onset of paracetamol absorption. The large variation could be explained 
by the length of the lag period prior to emptying, which is related to the 
principal motor reaction of the stomach after food ingestion, i.e. the 
accommodation reflex and the retropulsive antral contractions (Hasler, 
2008). Non-disintegrating dosage forms will be retained in the stomach 
until the recurrence of the IMMC activity in the upper GIT, i.e. for more 
than 4 h after administration of the standard meal (Koziolek et al., 
2016). 
2.2. Small intestinal phase 
2.2.1. Intestinal transit times 
Although the small intestinal transit time (SITT) of oral drug prod-
ucts is often reasonably predictable, the presentation of the drug for 
absorption depends on various factors. These include the properties of 
the drug product (e.g. disintegration behavior), matrix characteristics as 
well as the individual gastrointestinal physiology (e.g. motility, dietary 
habits). In particular, for drugs with low permeability (BCS class 3 and 4 
drugs) and those with limited absorption in the colon, the SITT may be of 
critical importance for drug absorption (Sugihara et al., 2015). Specif-
ically, a drug product may have a SITT too short for dissolution or for 
absorption. Furthermore, there may also be a preferred region for drug 
absorption in the small intestine (absorption window). This is usually 
encountered in the upper small intestine, where the drug dissolved in the 
stomach remains supersaturated as it enters the intestine in chyme for a 
variable time before nucleation and precipitation. Moreover, the 
expression of uptake and efflux transporter as well as of 
drug-metabolizing enzymes also varies along the GIT, which can lead to 
regional differences of drug absorption (Drozdzik et al., 2014; Fritz et al., 
2018). 
Various methods are available to assess the variability of intestinal 
transit times for liquids as well as solid objects. These include methods 
based on PK markers [e.g. combined use of paracetamol (gastric 
emptying marker) and sulfasalazine (colon arrival marker)], scintig-
raphy, magnetic marker monitoring (magnetic marker monitoring), 
magnetic resonance imaging as well as telemetric capsules (Hens et al., 
2017). It should be noted that the in vivo technique itself as well as the 
study protocol can also contribute to the variability (see Table 2). 
Typically, a range of 3 – 4 h is presented in the literature for SITT, 
being less variable as compared to gastric and colonic transit time. This 
value is in line with a meta-analysis on SITTs of single- and multiple-unit 
dosage forms that was recently published (Abuhelwa et al., 2016). In this 
work, the meta-mean SITT was 3.49 h and the meta-SD was 1.02 h. 
Thereby, the mean SITT was neither affected by the prandial state nor 
the type of dosage forms. Overall, similar values were observed for 
multiple and single-unit dosage forms. Further studies have also shown 
that SITT is not affected by the size of the object investigated, age and 
sex (Davis et al., 1986; Khosla et al., 1989). 
However, by having a closer look into different studies it is obvious 
that the SITT can also vary considerably and that certain aspects must be 
taken into deeper consideration. Published data from telemetric 
Fig. 1. Buffer capacity (BC) of antral contents 
of healthy adults in the fasted state vs. the 
corresponding pH values estimated after titra-
tion with NaOH (data from (Kalantzi et al., 
2006; Litou et al., 2016), squares and circles, 
respectively, n=60 individual samples mea-
surements). The insert shows individual data 
estimated after titration of aspirates collected 
from healthy adults who had been treated with 
famotidine (data from (Litou et al., 2016), n=16 
individual measurements) (modified from 
(Litou et al., 2020)).   
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capsules as well as from scintigraphy have demonstrated that the SITT 
can vary between less than 1 h and more than 10 h (Aburub et al., 2018; 
Davis et al., 1986; Fallingborg et al., 1990; Koziolek et al., 2015b; Peh 
and Yuen, 1996). Solid objects larger than 5 mm are typically emptied 
from the stomach only by strong peristaltic waves occurring during 
phase III of the Migrating Motor Complex in the fasted state. Since these 
peristaltic waves can move down to the ileum, their presence may 
explain exceptionally short SITT as they have been observed in some 
studies. Additionally, the aforementioned meta-analysis revealed that 
an increased caloric content of the test meal results in a reduced vari-
ability in SITT of solid dosage forms. Moreover, Adkin et al. have shown 
that some excipients (e.g. mannitol) used in oral drug delivery can also 
affect the SITT of oral dosage forms (Adkin et al., 1995a). An excellent 
summary of the effects of various excipients on SITT was provided in a 
review by Yuen (Yuen, 2010). Moreover, certain drugs (e.g. opioids, 
metoclopramide erythromycin, laxatives) are known to affect GI 
motility and by this, they may also affect the SITT (Deane et al., 2009; 
Litou et al., 2019). Interestingly, some drugs such as erythromycin can 
accelerate gastric emptying, but seem to have little effect on small in-
testinal transit time (Deane et al., 2019). It can be expected that absolute 
variability will be reduced in case of prokinetic drugs, but conclusive 
literature on this question could not be identified. 
An interesting study has been published by Ibekwe et al., in which the 
transit behavior of the Bravo pH capsule and a tablet coated with 
Eudragit S was studied by scintigraphy (Figure 2) (Ibekwe et al., 2008). 
As can be seen from Figure 2, the variability that was observed for the 
SITT in the aforementioned studies represents the sum of the variability 
of transit through the upper small intestine as well as the residence time 
at the ileocecal junction, an area serving as a reservoir. Both times can be 
variable and depend on further factors. The residence time at the ileo-
cecal valve is mainly controlled by the gastroileal reflex, which repre-
sents a physiological mechanism that enables the transfer of small 
intestinal contents into the caecum upon intake of food and drinks 
(Deiteren et al., 2010). Therefore, the dietary regime, in particular 
subsequent meals or drinks, can have dramatic consequences for the 
SITTs and orocecal transit times in clinical studies as it affects the 
transfer of material from the ileum to the cecum (Priebe et al., 2006; 
Priebe et al., 2004). 
The variability of transit times through certain parts of the small 
intestine is also of interest, in particular for drugs with pronounced 
regional differences in absorption (e.g. levodopa (L-DOPA), furose-
mide). Unfortunately, little is known about regional transit time as the 
visualization of dosage forms along with exact localization within the 
small intestine is hampered by the complex anatomy and therefore, 
often not possible. Nonetheless, imaging techniques such as scintigraphy 
and magnetic marker monitoring have been used in the past for the 
purpose of determining regional transit times. For instance, magnetic 
marker monitoring data have shown that the transfer through the duo-
denum is typically fast (Weitschies et al., 1999). In addition, the appli-
cation of these techniques has also revealed that the transit of dosage 
forms through the small intestine is not a continuous process but char-
acterized by alternating phases of low and high transit velocities. 
Thereby, dosage forms are in rest most of the time (Weitschies et al., 
2005). Multiple-unit formulations as well as formulations disintegrating 
in the stomach were further shown to spread within the small intestine 
before re-grouping again in the ileum (Khosla et al., 1989). The disper-
sion within the small intestine was mainly affected by the kinetics of 
gastric emptying (Yuen, 2010). 
Apart from SITTs of solid objects, pharmaceutical scientists are also 
interested in assessing the transit of solutions and suspensions. A meta- 
analysis of scintigraphic data in 1986 suggested that SITT of solutions, 
multiple-unit and single-unit formulations are in the same range (Davis 
et al., 1986). In contrast, Kellow and colleagues administered a sus-
pension containing 2 g of sulfasalazine directly into the duodenum of 
three healthy subjects. Interestingly, the time until sulfapyridine, a 
degradation product indicating colon arrival, could be detected varied 
between 90 and 140 min (Kellow et al., 1986). This data set suggests that 
liquids may be transferred quicker through the small intestine as 
compared to solid objects. However, further information is needed to 
confirm this hypothesis. 
Although large variability in SITTs has been shown for different oral 
dosage forms, only a few studies have linked changes in SITT with 
changes in PK parameters. It seems obvious that for drugs with poor 
permeability longer exposure times would lead to higher drug absorp-
tion, but despite its relevance, this effect has not been well studied yet. 
Riley and co-workers have shown that for two poorly permeable drugs, 
atenolol (BCS class 3) and hydrochlorothiazide (BCS class 4), an 
increased osmotic load results in limited drug absorption (Riley et al., 
1992). As compared to administration with water, the AUC of these 
drugs is clearly lower if they are co-administered with solutions con-
taining high osmotic loads. However, it should be noted that high os-
motic loads can also change the fluid volumes present in the small 
Table 2 
In vivo methods used to characterize SITTs.  
Technique Short description Limitations 
PK markers Determination of SITT of 
solutions by calculating the 
difference between the onset of 
plasma concentrations for 
gastric emptying marker (e.g. 
paracetamol) and colon arrival 
marker (e.g. sulfasalazine) 
Less suitable for solid objects 
as drug release occurs with a 
certain delay 
Scintigraphy Assessment of SITT based on 
image analysis. Useful for 
monitoring dispersion of drug 
formulation in the GIT 
Lack of anatomical 





Assessment of SITT based on 
analyzing the tracking data of a 
magnetically labelled object 
Limited availability of the 
equipment, lack of 
anatomical information, 




Assessment of SITT based on 
image analysis 
Often limited by the 
frequency of imaging 




Assessment of SITT based on 
characteristic pH changes in 
the GIT lumen 
Colon arrival not always 
clearly detectable, no 
information about transit 
behavior within the small 
intestine as there are no pH 
‘landmarks’.  
Fig. 2. Variability of transit times of Bravo® pH capsule (left hand side) and a 
tablet (diameter: 8 mm; right hand side) coated with Eudragit® S in 8 fasted, 
healthy subjects. GET – gastric emptying time, Upper SI – upper small intestinal 
transit time, ICV - residence time at the ileocaecal valve, CA – caecal arrival 
time. The figure is based on data published by Ibekwe and colleagues (Ibekwe 
et al., 2008). 
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intestine and thus, may also result in changes of intraluminal drug 
concentration (Grimm et al., 2018b). The effects seen in this study may 
not only result from changed transit times and therefore, further studies 
are needed to investigate the link between transit time and drug ab-
sorption in humans. In addition, in silico investigations can also be 
applied to study the effect of variability in SITT on drug absorption 
(Willmann et al., 2009). 
2.2.2. Intestinal fluid volumes and pockets 
The described transit of dosage forms or drug substances always 
needs to be evaluated considering the available amount of dissolution 
medium and its physicochemical properties. It is very likely that not only 
different transit times, but also different media volumes and composi-
tions contribute to PK variability. 
The available fluid volume plays a key role in dissolution and ab-
sorption processes as it determines the concentration arising from a 
specific dose of a drug (Koziolek et al., 2016; Sutton, 2009; Yu et al., 
2017). This role of fluid volume represents a general consent mainly 
based on physical laws like the Noyes-Whitney equation for dissolution 
rate and Fick’s laws of diffusion. Depending on dosage form and phys-
icochemical properties of the drug, a change in the available intestinal 
volume can lead to increased or decreased bioavailability (Grimm et al., 
2018b; Karsdal et al., 2008; Koziolek et al., 2016; Sunesen et al., 2005). 
Thus, the pronounced variability of freely available fluid in the small 
intestine is of high relevance and needs to be considered accordingly. 
After overnight fasting, very different average values of small bowel 
water content (SBWC) within representative young and healthy study 
populations were observed with values of 51 ± 34 mL (n=24), 91 ±
68 mL (n=16), 43 ± 14 mL (n=12) and 105 ± 72 mL (n=12), respec-
tively (Grimm et al., 2018b; Marciani et al., 2010; Mudie et al., 2014; 
Schiller et al., 2005). Although all measurements were performed by T2 
weighted MRI, differences might not only be attributed to interindi-
vidual variability or differences between subject groups, but also 
methodical differences in volume quantification. Thus, statistical com-
parison of these studies or meta-analysis are not meaningful. Moreover, 
individual data would be lacking. Repeated measurements of the same 
subject group of six individuals revealed no significant differences in 
resting SBWC in fasted state between four consecutive study days by use 
of Friedman test (Grimm et al., 2018b). Nonetheless, the ranges from 
minimum to maximum volume in the aforementioned studies were 
impressive. The ranges amounted to 45–319 mL (Schiller et al., 2005), 
12–253 mL (Marciani et al., 2010) and 5–159 mL (Mudie et al., 2014) at 
starting conditions of common clinical studies. The range might be a 
better predictor for variability than standard deviations, as it depends 
less on the sample size. The rapid but variable gastric emptying not only 
leads to an increase in SBWC after intake of water with the dosage form, 
but also in its variability. In a study by Grimm et al., the mean SBWC 
amounted to 54 ± 42 mL (n=6) with a range of 18–121 mL after over-
night fasting. Nine minutes after intake of 240 mL of water, the vari-
ability was peaking with a range of 41–204 mL. This increase is only 
short lived, since, after 24 min, a mean SBWC of 45 mL with a range of 
18-134 mL was observed  (Grimm et al., 2018b). Due to the rapid dis-
tribution of fluid from the stomach through the jejunum and subsequent 
absorption, the available volume, its variability and its distribution are 
comparable to conditions before intake after approximately 45 min 
(Grimm et al., 2018b; Mudie et al., 2014). The SBWC and its variability in 
clinical trials under fasted conditions can be seen in Figure 3. 
Data on intraindividual variability under clinically relevant condi-
tions is lacking, but referring to data obtained for gastric volumes and 
gastric water emptying, it is very likely that also for SBWC, intra-
individual variability is comparable to interindividual variability 
(Grimm et al., 2018a). 
Besides the variability of cumulative small intestinal fluid volume, 
the small intestinal fluid distribution is characterized by variability. It is 
known that there is not one coherent volume in the small bowel, but that 
the volume is distributed in several discrete fluid pockets (Schiller et al., 
2005). MRI studies revealed a highly variable and dynamic distribution 
of fluid pocket quantity and pocket volume, as illustrated in Figure 4. A 
study by Schiller et al. reported a median number of 4 fluid pockets with 
a median volume of 12 mL (Schiller et al., 2005). In contrast, Mudie et al. 
reported a mean of 8 ± 1 pockets with a mean volume of 4 ± 1 mL 
(Mudie et al., 2014). These highly variable but small coherent volumes 
will also have implications on dissolution rate, local drug concentrations 
and eventually on absorption. 
Irrespective of the real number of pockets and their volume, these 
observations show that a dosage form in the small bowel might not 
necessarily have contact with a relevant amount of dissolution medium. 
It has been reported that, about 30 % of monolithic dosage forms had no 
contact and additional 20 % only had partial contact to intestinal fluids 
during transit after fasted administration (Schiller et al., 2005). Espe-
cially for enteric coated dosage forms, this variable contact with fluid 
pockets might explain the high variability of disintegration time after 
the gastric emptying of the dosage forms (Al-Gousous et al., 2017; 
Grimm et al., 2019; Wilding et al., 1992). 
Regarding small intestinal volumes, the postprandial intake of 
dosage forms under conditions representing typical clinical studies is 
insufficiently studied until now. Nonetheless, particular food compo-
nents were shown to have a specific effect not only on small intestinal 
volumes but also on its variability. For example, glucose is able to 
decrease variability of SBWC, whereas fructose can drastically increase 
it (Grimm et al., 2018b). 
Moreover, a decrease in the volume of free fluid and high interin-
dividual variability was observed after a meal, together with an increase 
in the number of fluid pockets (Schiller et al., 2005). But those evalua-
tions of free intestinal fluids in fed state conditions need to be inter-
preted and used with care. Since the small intestine is filled with an 
inhomogeneous slurry of partially digested food components, the 
determination of freely available water in fluid pockets in this chyme 
and water bound to chyme is highly dependent on imaging and analysis 
procedures. It is to be expected that the variability of free small intes-
tinal media is increased not only in terms of amount but also in distri-
bution. On the other hand, the small bowel might be filled more 
quantitatively after a large meal, so that variations due to erratic fluid 
contact could be reduced. 
The intake of oral dosage forms with or without food not only 
changes the volume available and its distribution, it can also cause 
dramatic changes in the physicochemical properties of the media. 
2.2.3. Chemical composition and colloidal aggregates in the small intestinal 
fluids 
The composition of human intestinal fluids changes constantly dur-
ing the day, leading to great inter- and intraindividual variability. In 
Fig. 3. Median of SBWC (black) with interquartile range (the difference be-
tween 75th and 25th percentiles) (grey) before (t = -1 min) and after intake of 
240 mL of water under fasted conditions (n=6)(Grimm et al., 2018b). 
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addition, the intake of food leads to different biliary/pancreatic secre-
tions, which further complicates the intestinal environment. Reported 
concentrations of the chemical composition of the GIT also depend on 
the study design (e.g. amount and timing of water intake, composition of 
the administered meal) and how the samples are handled and analyzed 
(Fuchs and Dressman, 2014). An overview of the chemical composition 
of small intestinal fluids in the fasted and fed state (without drug 
co-administration) and the associated variability is summarized in 
Tables S1 and S2 (available in the Supporting information). 
Bile salts. Bile salts are secreted into the upper GIT to aid in the solu-
bilization of lipophilic compounds. In the fasted duodenum, the total 
bile salt concentration reported in the literature ranges from 0.03 to 
36.18 mM (Table S1A in the Supporting information) (Riethorst et al., 
2016b). However, bile salt levels are generally considered to be low (<
5 mM) in the fasted state, resulting in an overall mean of 3.3 mM in the 
duodenum and 3 mM in the proximal jejunum (Fuchs and Dressman, 
2014). Reported high values are thought to be caused by sampling 
immediately after gall bladder emptying. In the fed state, a larger range 
in total bile salt levels was reported, namely between 0.74 and 
86.14 mM (median 9.59 mM) (Riethorst et al., 2016b). This range is 
broader compared to Bergström et al., who reported a range of 3.6 to 
24 mM (median 11.8 mM)(Bergstrom et al., 2014). In addition, the 
qualitative and quantitative composition of individual bile salts in the 
small intestine is highly variable (Table S1B in the Supporting infor-
mation). Taurocholate (TC), glycocholate (GC) and glycochenodeox-
ycholate (GCDC) together represent about 70 – 75 % of the total bile salt 
concentration in the fasted state small intestine (Fuchs and Dressman, 
2014; Persson et al., 2006). In both duodenum and jejunum, TC is most 
prevalent, followed by almost equivalent amounts of GC and GCDC 
(Fuchs and Dressman, 2014; Perez de la Cruz Moreno et al., 2006). In 
general, glyco-conjugated bile salts are more abundant than 
tauro-conjugated bile salts (70% vs. 30%, respectively) (Riethorst et al., 
2016b). The relative abundance of individual bile salts was reported to 
remain nearly constant over time for all volunteers in both fasted and fed 
states (Riethorst et al., 2016b). 
Phospholipids. Besides bile salts, phospholipids are also secreted with 
bile into the duodenum to aid in the solubilization of lipophilic com-
pounds. The most prevalent phospholipids found in the GIT are PC and 
its hydrolysis product lyso-phosphatidylcholine (lyso-PC). PC is hydro-
lyzed in the small intestine to lyso-PC and a free fatty acid by 
phospholipase-A2 and nonspecific lipases secreted by the pancreas. 
Persson et al. showed that 98.4 % of the total phospholipid content 
consists of lyso-PC (Persson et al., 2005). In the fasted state, a range of 
total phospholipids between 0.01 and 6.33 mM is reported with higher 
concentrations found in the fasted duodenum compared to the fasted 
jejunum (Table S1C in the Supporting information)(Bergstrom et al., 
2014; Fuchs and Dressman, 2014; Riethorst et al., 2016b). In post-
prandial conditions, higher levels of phospholipids can be detected as 
they can be present in food. The distribution of total phospholipids was 
reported to vary less after intake of a liquid meal but still, a large range 
from 0.16 to 14.39 mM was observed (Table S2C in the Supporting in-
formation)(Riethorst et al., 2016b). Phospholipids are known to influ-
ence the solubility of many compounds in a positive way. For example, 
the solubility of danazol, itraconazole, probucol, felodipine and fenofi-
brate increased with increasing phospholipid levels in simulated intes-
tinal fluids (Madsen et al., 2021; Zhou et al., 2017). The ratio of bile salts 
to phospholipids is also highly variable, ranging from 4.5 to 39 in the 
fasted state and from 1.3 to 16 in the fed state (Kleberg et al., 2010), 
influencing the formation and structures of mixed micelles. The solu-
bility of aprepritant was influenced positively by the bile salt to phos-
pholipid ratio (Madsen et al., 2018), while that of fenofibrate, felodipine, 
zafirlukast and danazol was influenced negatively (Madsen et al., 2018; 
Madsen et al., 2021). The effect on permeability, however, was not 
investigated. In an Ussing chambers experiment with rat tissue, phos-
pholipids decreased the permeation of propranolol and indomethacin 
(Riethorst et al., 2018a). However, to the best of our knowledge, a direct 
influence of phospholipids on drug pharmacokinetics is not known. 
Dietary lipids. In fasted state, cholesterol is only present in a low amount 
in the duodenum, ranging between 0 and 1.8 mM (Table S1C in the 
Supporting information) (Heikkila et al., 2011; Psachoulias et al., 2011; 
Riethorst et al., 2016b). In postprandial conditions, cholesterol con-
centrations increase due to bile secretions but also due to the presence of 
cholesterol in the meal. The range of cholesterol measured in the duo-
denum after intake of 400 mL of Ensure Plus (0.45 mM cholesterol 
content) was between 0 and 3.29 mM (Table S2C in the Supporting in-
formation) (Riethorst et al., 2016b). 
In fasted state human intestinal fluids (FaHIF), only FFA (0–3.86 mg/ 
mL) and monoacylglycerides (MAG; 0–1.09 mg/mL) were detected 
(Table S1C in the Supporting information). The FFA were probably 
derived from hydrolyzed phospholipids with C16/C18 chain lengths 
(Riethorst et al., 2016b). In the fed state, TAG and DAG originating from 
food degrade very rapidly and effectively to FFA and MAG in the small 
intestine. Hence, the majority of lipids present in duodenal fluids are 
degradation products. After intake of a liquid meal, the range of FFA, 
MAG, DAG and TAG were 0.53–15 mg/mL, 0–11.36 mg/mL, 
0–3.64 mg/mL, and 0–6.76 mg/mL, respectively (Table S2C in the 
Supporting information). Intake of a meal with a higher lipid content 
does not result in higher duodenal lipid concentrations (Armand et al., 
1996). 
Fig. 4. Clear differences in amount and distribution of fluids in 3D reconstructions of gastrointestinal water from four different subjects 9 min after intake of oral 
dosage form with 240 mL water in fasted state conditions. 
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The combination of increased lipid, phospholipid and bile salt con-
tent in the fed state generally enhances the solubility of lipophilic drugs 
due to their poor aqueous solubility. In particular, the intake of a high fat 
meal (e.g. the FDA breakfast) can lead to drastically improved oral 
bioavailability in case of oral anticancer agents lapatinib (4-fold), 
vemurafenib (5-fold)(Koziolek et al., 2019) and abiraterone acetate 
(10-fold)(Stappaerts et al., 2015). 
Enzymes. To aid in the digestion of various nutrients, the pancreas se-
cretes enzymes, such as lipase, amylase, trypsin and chymotrypsin. 
Enzyme secretions peak 20–60 min postprandially, especially after a 
high fat meal as lipids are the strongest stimulants of pancreatic enzyme 
secretion (Keller and Layer, 2005). Fasted state pancreatic lipase con-
centrations ranged between 23 and 86 µg/mL (corresponding to an ac-
tivity between 184 and 690 IU/mL) in the duodenum, whereas in the fed 
state, they increased 5- to 10-fold (Riethorst et al., 2016b). Pancreatic 
lipase is responsible for 40 to 70 % of TAG hydrolysis (Armand, 2007). In 
addition, amylase and trypsin concentrations increase 3–6 fold after a 
meal (Keller and Layer, 2005). Duodenal phospholipase-A2 concentra-
tions ranged between 3 and 6 ng/mL in the fasted state and increased 
5-fold in the fed state (Riethorst et al., 2016b). In addition, an increase in 
esterases can be observed, influencing the conversion of ester prodrugs 
(Riethorst et al., 2016b). Although a considerable variation in the 
enzyme levels both in the fasted and the fed state is described in liter-
ature, studies that determine the enzyme activity in parallel with drug 
pharmacokinetics are required to reveal the clinical impact of enzyme 
variability. 
Colloidal structures. Besides the variable nature of the intestinal 
composition, the assembly of different colloidal structures in the GIT has 
a highly dynamic nature, influenced by variables such as motility, se-
cretions, intestinal transfer and digestion. Bile salts are able to associate 
in aqueous media, forming micelles. In the presence of phospholipids, 
cholesterol and lipolytic hydrolysis products, mixed micelles are formed 
with higher solubilization capacity. PC generally forms vesicles, lipo-
somes, bilayer sheets or lamellar structures in the GIT due to the very 
low aqueous solubility. Lyso-PC, however, is able to form micelles, 
giving rise to more stable colloidal structures compared to PC. 
In FaHIF, only simple (bile salt/phospholipid) micelles ranging be-
tween 10 and 50 nm in size could be detected but no vesicles (Riethorst 
et al., 2016a). In another study, few multi- and oligolamellar vesicles 
were observed 30 and 60 min after administration of an aqueous 
dipyridamole solution in the fasted state (Mullertz et al., 2015). The 
intraluminal environment gets more complex in the fed state, containing 
(mixed-)micelles (10 and 100 nm), large clusters of mixed-micelles and 
vesicles (100 and 500 nm), and lipid droplets (≥ 2 µm) (Riethorst et al., 
2016a). Riethorst et al. found far less multilaminar vesicles than re-
ported by Müllertz et al (Mullertz et al., 2012; Riethorst et al., 2016a). 
Multicompartmental vesicles, however, were common (Riethorst et al., 
2016a). However, the intestinal composition and ultrastructure of in-
testinal aspirates vary over time and amongst individuals. In general, fed 
state human intestinal fluids (FeHIF) containing high concentrations of 
bile salts were found to display a more complex ultrastructure, including 
small mixed-micelles, whereas FeHIF containing high lipid concentra-
tions was characterized by vesicles and lipid droplets (Elvang et al., 
2019; Riethorst et al., 2018b). Nevertheless, composition does not 
directly translate into ultrastructure (Riethorst et al., 2016a). 
Effect of chemical composition on solubility and ultrastructure. Data link-
ing a specific factor of the chemical composition of intestinal fluids to 
drug release and dissolution in the human GIT are scarce. One way to 
investigate this is to aspirate intestinal fluids over time after drug intake 
or to look at specific disease states, which will be discussed later on (see 
section 4). For instance, the absence of intestinal bile flow in patients 
undergoing liver transplantation did not influence the absorption of 
tacrolimus (Böttiger et al., 2002). In vitro solubility and permeability 
studies using blank FaHIF and FeHIF are more abundant in literature, 
which provides an idea on how drugs will behave in vivo. However, the 
high variability in solubility of different compounds not only across 
volunteers and sampling sites but also in function of time in different 
nutritional states is reported (Clarysse et al., 2009a; de la Cruz-Moreno 
et al., 2017). This reported variability is the highest for highly lipo-
philic compounds and for compounds with a pKa value within the 
physiological pH range. Augustijns et al. summarized solubility data of 
59 different compounds in FaHIF and 28 different compounds in FeHIF 
(Augustijns et al., 2014). Postprandial conditions increased the solubi-
lizing capacity of 24 of the 28 compounds tested but no correlation could 
be found between the solubility and presence of bile acids and/or 
phospholipids. A more pronounced interindividual variability in solu-
bility in the more complex fed state was also observed for different 
protease inhibitors, which suffer from a low bioavailability due to 
intraluminal solubility and dissolution issues and first-pass elimination 
(Wuyts et al., 2013). This interindividual variability in both fasted and 
fed state is visualized in Figure 5. The average coefficient of variance 
(CV) amounted to 40.4% and 60.6% in the fasted and fed state, 
respectively (Wuyts et al., 2013). The extent of drug solubilization is not 
only dependent on the chemical composition of intestinal fluids, but also 
on the ultrastructure (Riethorst et al., 2018b). The solubility of different 
lipophilic compounds increased when including the lipid layer of HIF, 
meaning that the structures in the lipid layer (e.g. vesicles, lipid drop-
lets) play a significant role in solubilizing these compounds. It is, how-
ever, unclear what the fate of compounds solubilized in these larger 
colloidal structures is. Entrapment of lipophilic compounds in colloidal 
structures has been shown in vitro (Stappaerts et al., 2014; Wuyts et al., 
2015a, 2015b). The negative food effect observed in vitro for metoprolol 
and darunavir could be attributed to entrapment by lipid structures 
Fig. 5. Interindividual variability of the solubility of human immunodeficiency 
virus (HIV) protease inhibitors in (A) fasted and (B) fed human intestinal fluids. 
Data from fluids aspirated from four individuals and pooled intestinal fluids 
(Wuyts et al., 2013). 
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rather than influence by the bile salts and phospholipids present in SIF 
(Riethorst et al., 2018a). Using β-blockers with different physicochem-
ical properties, Stappaerts et al. observed that micellar entrapment 
increased with increasing lipophilicity, causing a decrease in absorptive 
flux in the fed state compared to the fasted state in the in situ rat 
perfusion model (Stappaerts et al., 2014). It should be noted that the in 
vivo intestinal environment is highly dynamic and colloids change as 
digestion progresses, possibly resulting in higher absorptive flux. 
Nevertheless, predicting the in vivo behavior of drugs remains chal-
lenging due to the highly variable nature of both chemical composition 
and ultrastructure of intestinal fluids. 
2.2.4. Intestinal pH and buffer capacity 
As in the corresponding section of the gastric phase, this section fo-
cuses on the variability of data in fasted adults, after a glass of water 
(fasted state) and the variability of data in fasted adults after the stan-
dard meal (fed state). 
In the fasted state, the average pH in the upper small intestine is near 
neutral with reported median values ranging from 6.1 to 7.0. Reported 
pH values seem to not follow normal or log-normal distributions (Pyper 
et al., 2020). However, during the first hour after water administration, 
variability is high and pH values as low as 3 could be occasionally 
observed (Vertzoni et al., 2019). The resistance of contents of the upper 
small intestine to decrease in one pH unit when titrating with HCl does 
not seem to be related to the pH and it is highly variable (Figure 6). In 
vitro data indicate that both the buffer capacity and the pH of bicar-
bonate solutions up to 30 mM are affected by subjecting the samples to a 
freeze-thaw cycle (Litou et al., 2020). Since subjecting aspirates to a 
freeze-thaw cycle does not significantly affect the pH of aspirates from 
the upper small intestine, it appears that species other than bicarbonates 
e.g. enzymes and/or mucin glycoproteins, may play an important role in 
regulating the intraluminal pH (Litou et al., 2020). This possibility is also 
supported by data concerning the importance of bicarbonates in bio-
relevant media simulating the conditions in the stomach under elevated 
gastric pH conditions and in the upper small intestine in the fasted state 
(Litou et al., 2016; Litou et al., 2017). 
In the fed state, the overall median pH value for the period between 
60 and 240 min, after initiation of administration of the standard meal, 
has been reported to be 6.3 (Dressman et al. 1990) and 5.3 (Pentafragka 
et al., 2020b). Intraindividual variability in pH values has been reported 
to be low and similar to that in the stomach (Pentafragka et al., 2020b). 
During the first four hours after initiation of meal administration, buffer 
capacity values in the upper small intestine in the fed state are similar to 
those measured in the stomach in the fed state. Also, during the first four 
hours after meal administration, the average difference in buffer ca-
pacity values between two administrations in a given individual ranges 
from -50 % to 30 % in the upper small intestine, i.e. intraindividual 
variability of buffer capacity can be quite high. 
Regardless of the dosing conditions, the pH in the distal ileum 
(20–30 cm from the ileocecal valve) is about pH = 8.0 and the buffer 
capacity is within the range of values reported for the upper small in-
testine in the fasted state (Reppas et al., 2015). However, data from more 
individuals are needed to confirm these findings. 
2.2.5. Viscosity and osmolality of small intestinal contents 
For the upper small intestine, viscosity data in the fasted state are 
limited, however, values seem to be similar or slightly higher than that 
of water (Pentafragka et al., 2020a). After the standard meal, rheological 
characteristics are pseudoplastic and viscosity is highly variable. 
Compared at a shear rate of 100 s− 1, the average viscosity is at least 100 
times higher than in the fasted state (Pentafragka et al., 2020a). In vitro 
and in silico data suggest that concomitant food intake can diminish oral 
absorption of drugs with limited permeability and an absorption win-
dow in the proximal intestine, due to viscosity-mediated decrease in 
dosage form disintegration time and drug dissolution rates (Cvijic et al., 
2014). In the distal ileum, the liquid fraction and the size of non-liquid 
particles has been measured in the fasted (glass of water) and fed 
(standard FDA meal) state, 5 h after liquid or food ingestion (Reppas 
et al., 2015). The liquid fraction was significantly lower in the fed state 
(69 %) compared with the fasted state (90 %). The volume mean 
diameter of non-liquid particles was slightly higher than 200 µm, 
regardless of the dosing conditions. 
Contents of the upper small intestine in the fasted state are almost 
iso-osmotic (Pentafragka et al., 2019). After the standard meal, contents 
become hyperosmotic (values are on average less than 400 mOsm/kg) 
between t = 90 and 180 min after food ingestion (Pentafragka et al., 
2020a). Low osmolarity of a nutrient solution mediates an increase in 
water absorption from the small intestine and it lowers water flow along 
the upper small intestine (Pfeiffer et al., 1998). 
In the distal ileum, contents are generally hypoosmotic with the 
mean value in the fasted state (60 mOsmol/kg) being significantly lower 
than the mean value in the fed state (252 mOsmol/kg) (Reppas et al., 
2015). 
When changes in osmolality are mediated primarily via changes in 
ionic strength, drug release characteristics from certain modified release 
products may (Mikac et al., 2010; Verhoeven et al., 2006) or may not (Li 
et al., 2013; Rahmouni et al., 2001) be significantly affected. 
2.2.6. 2.2.6. Epithelial permeability 
The absorption of a drug following oral administration is a complex 
process that depends on the physicochemical properties of the drug, 
pharmaceutical formulation, and physiological and anatomical vari-
ables in the GIT (Koziolek et al., 2019; Williams et al., 2013). Once a drug 
is in solution in the gastrointestinal lumen, the absorption of the drug 
depends to a large extent on permeability of the epithelium of the small 
intestine since the small intestine is the major site of absorption of most 
drugs (Williams et al., 2013). Drugs can pass across the intestinal 
epithelial layer via either paracellular, transcellular, or carrier-mediated 
facilitated transport. Transport across the intestinal epithelial layer can 
be enhanced by the manipulation of drug physicochemical properties 
and structure (Laksitorini et al., 2014). For example, increasing lip-
ophilicity and reducing ionization can enhance passive permeability 
(Williams et al., 2013) whereas conjugation of drugs with endogenous 
substrates for intestinal transporters can lead to facilitated transport 
(Zhang and Wu, 2014). 
Any factor (physiological, pathological, or pharmacological) that 
alters intestinal epithelial permeability might affect the oral absorption 
of drugs. This is particularly true for drugs with permeability (rather 
than solubility) limited absorption (Williams et al., 2013). Many disease 
states are associated with altered intestinal epithelial permeability as 
further discussed in section 4, including intestinal inflammatory diseases 
(Buchman et al., 2005), infections (Allam et al., 2018), short bowel 
syndrome (Tappenden, 2014), critical illness (Fink, 2003) and Alz-
heimer’s disease (Jin et al., 2020). Whilst pathological changes in 
Fig. 6. Buffer capacity (BC) of contents in the upper small intestine in the 
fasted state vs. the corresponding pH values estimated after titration with HCl 
(data from two studies, squares and circles, n=45 individual samples mea-
surements) (modified from Litou et al. 2020). 
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intestinal epithelial permeability have been shown to alter nutrient 
absorption, their impact on the absorption of drugs has rarely been 
quantified (Jin et al., 2020). 
In addition to disease states, many other factors can increase intes-
tinal epithelial permeability including dietary components (Rohr et al., 
2020), alcohol (Wang et al., 2014), microbial by-products (Guo et al., 
2017), strenuous exercise (Dokladny et al., 2016), certain medications 
(Scarpignato and Bjarnason, 2019) and aging (Man et al., 2015). The 
impact of diet, supplements and pharmaceutical formulations on intes-
tinal epithelial permeability has been most widely studied. Pharma-
ceutical permeability enhancers are purposely used to increase drug 
absorption through either paracellular or transcellular pathways, as 
reviewed (Aungst, 2012). Gut-microbiota modifiers (probiotics and 
prebiotics) (Guo et al., 2017) and modulators of tight junction function 
(e.g. zonulin antagonists) (Smyth, 2017) can decrease intestinal 
epithelial permeability although the effect on drug absorption has been 
rarely studied. Western style diets (high in fat and carbohydrate while 
low in fibers) are generally associated with increased paracellular 
permeability (Rohr et al., 2020). On the contrary, certain dietary com-
ponents (e.g. polyphenols) can decrease intestinal epithelial perme-
ability (Bernardi et al., 2019). In addition to diet type, malnutrition and 
fasting can cause duodenal atrophy and increased intestinal epithelial 
permeability (Ferraris and Carey, 2000). Alterations in epithelial 
permeability by diet factors are typically mediated by changes to the 
function of tight junctions between epithelial cells. 
Diet and other factors (such as formulation components, ageing, 
genetics and disease states) can also affect drug passage across the in-
testinal epithelium through induction or inhibition of enterocyte-based 
metabolism by phase 1 and/or 2 enzymes, and influx or efflux between 
the enterocyte and intestinal lumen by transporters such a P-glycopro-
tein (Benet et al., 1999). For example, genetic variations in intestinal 
metabolism and/or transporters (influx and efflux) might lead to inter-
individual variation in drug response (Ahmed et al., 2016). However, the 
impact of genetic polymorphisms of intestinal efflux transporters and 
metabolic enzymes on drug absorption has so far found to be minimal 
(Tomalik-Scharte et al., 2008). In Crohn’s disease, P-glycoprotein 
expression in the intestine is increased by 200% and this might explain 
the higher dose of tacrolimus needed in these patients (Buchman et al., 
2005). In a familial Alzheimer’s disease mouse model, the intestinal 
epithelial permeability of digoxin and valsartan was significantly 
reduced and this could be explained by enhanced expression of intesti-
nal efflux transporters (Jin et al., 2020). It is thus evident that a range of 
factors may impact the intestinal permeability of drugs. The impact of 
disease states on oral drug absorption is further described in section 4. 
2.2.7. Absorption into lymph and blood 
After drugs permeate the intestinal epithelium, they are transported 
from the intestine by either blood or lymphatic capillaries in the un-
derlying lamina propria (Trevaskis et al., 2015) (Figure 7). 
Most small molecule drugs distribute into blood capillaries. This has 
been suggested to result from the ~500 fold higher flow rate of blood 
compared with lymph flow from the intestine (Charman and Stella, 
1986). Conditions that alter splanchnic blood flow have the potential to 
impact drug absorption into blood. For example, absorption of the 
model drugs sulfaethidole and haloperidol into blood after oral admin-
istration was reduced in dogs with reduced splanchnic blood flow 
(Crouthamel et al., 1975). Splanchnic blood flow is regulated by the 
autonomic nervous system and vasoactive mediators, and is impacted by 
many factors such as food intake, exercise, drugs and disease states. 
Splanchnic blood flow typically increases after meals depending on the 
type of food, while it decreases with fasting and exercise (Koffert et al., 
2017; Perko et al., 1998). The impact of food on oral drug absorption is, 
however, complicated as food affects many processes involved in oral 
drug absorption (Koziolek et al., 2019). Some drugs can affect splanchnic 
blood supply which might affect the absorption of other drugs. For 
example, digitalis is a potent vasoconstrictor and once absorbed can 
cause a 30–40 % decrease in splanchnic circulation (Crouthamel et al., 
1975). Many disease states are associated with reduced splanchnic blood 
flow such as congestive heart failure, haemorrhage and critical illness 
(Fink, 2003). On the contrary, liver cirrhosis is typically associated with 
increased splanchnic blood flow (Bolognesi et al., 2014). Any alteration 
in splanchnic blood flow might affect drug absorption, however, this has 
not been evaluated for most factors. 
Whilst most small molecule drugs are absorbed from the intestine 
into the blood, highly lipophilic drugs and prodrugs (typically with log P 
> 5 and long chain lipid solubility >50 mg/g) can be transported from 
the intestine via lymphatic vessels (Trevaskis et al., 2015). This is 
mediated by drug association with the lipid-rich lipoproteins (primarily 
chylomicrons) that are assembled in enterocytes from dietary and 
endogenous lipids (Trevaskis et al., 2015)(Figure 7). 
Chylomicrons are transported from the intestine via the lymphatic 
system as the blood vessel endothelium is less permeable than the 
lymphatic endothelium, precluding the access of chylomicrons that are 
100–1000 nm in diameter. In contrast, the initial lymphatics (lacteals) in 
intestinal villi contain specialised openings between endothelial cells 
that facilitate the entry of chylomicrons (Zhang et al., 2018). However, 
some studies have also suggested a transcellular pathway into lacteals 
and that small chylomicrons might be able to distribute into blood 
capillaries (Dixon, 2010). Following entry into lacteals, chylomicrons 
(and associated drugs) distribute into mesenteric lymphatic vessels that 
flow into the thoracic duct, which joins the systemic circulation at the 
subclavian vein. 
Many factors influence chylomicron production and transport 
through the mesenteric lymphatic system and may thus impact intestinal 
lymphatic drug transport. For example, drug association with chylomi-
crons is potentiated by administration with a lipid source such as food or 
a lipid-based formulation (Trevaskis et al., 2015). The type and dose of 
co-administered lipid can dramatically alter the extent of lymphatic 
drug transport (Caliph et al., 2000; Trevaskis et al., 2020). For example, 
long-chain lipids such as found in olive oil, peanut oil and soybean oil 
are assembled into chylomicrons and thus increase lymphatic transport 
Fig. 7. Distribution of small molecule drugs into blood or lymph following 
uptake into enterocytes from the intestinal lumen. Drugs transported via the 
lymphatic system bypass the liver and reach the systemic circulation via the 
thoracic lymph duct. 
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of chylomicrons and lipophilic drugs. In contrast, short and 
medium-chain lipids (e.g. in coconut oil) are typically transported from 
the intestine via the draining blood capillaries and do not stimulate 
lymphatic transport of chylomicrons and drugs (Caliph et al., 2000). For 
model drugs halofantrine and methylnortestosterone lymphatic trans-
port increased with long-chain lipid doses up to ~130 mg/kg and then 
appeared to plateau at a maximum across several species (Trevaskis 
et al., 2020). The extent of lymphatic transport is thus highly variable 
depending on the co-administered lipid dose with maximum lymphatic 
drug transport seen in the fed state and minimal lymphatic transport 
seen in the fasted state (Trevaskis et al., 2015). Non-lipid based food 
components can also affect chylomicron production; chylomicron pro-
duction is increased following acute oral intake of monosaccharides 
such as glucose and fructose (Xiao et al., 2013), while chylomicron 
production is reduced following acute ingestion of monosodium gluta-
mate (Kohan et al., 2016). Ethanol consumption also modulates chylo-
micron production (Baraona and Lieber, 1975). A range of drugs 
modulate lymphatic lipid transport including pancreatic lipase in-
hibitors, glucagon like peptide-1 agonists, dipeptidyl peptidase-4 in-
hibitors, and modulators of lipoprotein metabolism such as fibrates and 
cholesterylester transfer protein (CETP) inhibitors (Dash et al., 2015; 
Trevaskis et al., 2010; Xiao et al., 2012). In addition, chylomicron pro-
duction has been found to decrease after surgeries such as sleeve gas-
trectomy (Padilla et al., 2014). Many disease states affect chylomicron 
production. For example, type 2 diabetes mellitus is associated with 
increased chylomicron production, while in abetalipoproteinemia (a 
rare genetic condition) chylomicron production is impaired (Dash et al., 
2015). Any alteration in chylomicron synthesis and secretion has the 
potential to alter the absorption and/or lymphatic transport of lipophilic 
drugs and prodrugs, however, this has not been proven for all factors 
listed above. 
Factors that regulate chylomicron uptake into and transport through 
lymphatic vessels following secretion from enterocytes are beginning to 
be elucidated and have the potential to impact lymphatic drug transport. 
As mentioned above, chylomicrons predominantly enter lacteals via 
paracellular transport such that any factor that closes lacteal junctions 
will preclude chylomicron uptake (Zhang et al., 2018). For example, 
vascular endothelial growth factor-C (VEGF-C) mediates the develop-
ment and maintenance of intestinal lymphatics, including lacteals. De-
fects in Vegfc gene expression lead to atrophy of the lacteals and a 
substantial reduction in lipid absorption (Nurmi et al., 2015). The flow 
of lymph from the intestine and thus lymphatic lipid transport is also 
influenced by active pumping of the smooth muscle cells surrounding 
lacteals (Choe et al., 2015) and mesenteric collecting lymphatic vessels 
(Zawieja et al., 2012). In rodent models of metabolic syndrome, the 
contractility of the mesenteric collecting lymphatics is negatively 
affected, which affects lymph flow and absorption of chylomicrons 
(Zawieja et al., 2012). Similarly, in inflammatory bowel disease (IBD) 
there is significant lymphatic remodelling including lymphangiogenesis, 
lymphatic vessel dilation and leakiness, and impaired contractility 
which impairs lipid absorption (Stephens et al., 2019). Absorption of 
lipophilic drugs and prodrugs might be affected by conditions such as 
this that alter the transport of chylomicrons via the lymphatics. 
Alterations to drug absorption via the blood versus the lymphatic 
system can in turn impact the oral bioavailability of drugs with high first 
pass hepatic metabolism as the mesenteric capillaries and veins join the 
portal vein which flows to the liver before reaching the systemic circu-
lation. In contrast, the intestinal lymphatics join the thoracic lymph duct 
which empties into the systemic circulation directly without passing 
through the liver. For example, administration of the highly lipophilic 
drugs and prodrugs halofantrine, cannabinoid receptor agonist CRA13, 
testosterone undecanoate and methyl nortestosterone undecanoate with 
a lipid source (e.g. a meal) substantially increases oral bioavailability by 
promoting lymphatic uptake and avoiding passage through the liver 
(Khoo et al., 2001; Shackleford et al., 2003; Trevaskis et al., 2009; White 
et al., 2009). Overall, many anatomical and physiological factors 
modulate the intestinal absorption of lipids and transport of chylomi-
crons into the lymph, which could impact drug oral bioavailability. 
2.2.8. Enterohepatic circulation 
Excretion via the biliary and intestinal routes could be important for 
the elimination of drugs and metabolites from the body, thus creating an 
additional source of variability. It is common that drugs excreted via the 
biliary pathway have been metabolized by phase II enzymes within 
hepatocytes and then transported into bile, and for those which have 
been directly degraded by phase II enzymes, intestinal deconjugation 
and reabsorption as intact substance might occur (Roberts et al., 2002; 
Shou et al., 2005). The phenomenon when a compound is excreted via 
bile into the small intestine and then reabsorbed and excreted into bile 
again (wholly or partly) is called enterohepatic circulation (EHC) 
(Roberts et al., 2002). Biliary elimination is the most predominant 
non-renal elimination route of drugs and drug metabolites, which is 
affected by factors like compound characteristics (molecular weight, 
size, structure and polarity), species, age, sex differences, genetic fac-
tors, co-administered drugs, biotransformation, food and bile acid 
sequestrants, drug transport across different barriers (membranes and 
transporters), disease conditions and diurnal variations (Malik et al., 
2016). Diet in particular has been demonstrated to significantly impact 
bile pool size and turnover (Adlercreutz et al., 1987; Bisschop et al., 
2004; Hepner, 1975). This can in turn have a significant effect on the PK 
and exposure variability of drugs, where EHC is known to contribute to 
its disposition. As a result, considerations need to be given to food intake 
during clinical studies, so as to not confound reasons for variability in 
the PK data. This was demonstrated for rifapentine, whose exposure can 
be substantially impacted by food: using population PK modeling with 
appropriate covariate analysis, the authors were able to prove that the 
double peaks observed in rifapentine PK profiles and exposure vari-
ability were not due to EHC (Zvada et al., 2010). The authors speculated 
that these could be due to a combination of absorption windows in the 
GIT, progressive solubilization along the GIT and variable gastric 
emptying. 
Various endogenous as well as exogenous compounds are known to 
undergo EHC, which may serve a physiological function, for example in 
the recycling of bile acids. Maintenance of bile acids circulation is 
imperative for several liver and gastrointestinal functions including bile 
flow, clearance of toxins, solubilization and excretion of cholesterol, 
enhanced intestinal absorption of lipophilic nutrients, as well as meta-
bolic and antimicrobial effects (Abu-Hayyeh et al., 2013; Li and Chiang, 
2015; Roberts et al., 2002). 
The EHC process can be divided into several components: (1) ab-
sorption of drug(s) from the GIT into the portal blood supply, (2) 
metabolism and efflux by the gut wall, (3) transport from the portal 
blood across the hepatocyte membranes, (4) transport from the hepa-
tocyte membrane to metabolizing sites and to the bile canniculae, (5) 
biotransformation in the liver, (6) transport from the hepatocytes across 
the canalicular membrane into the bile, (7) active transport from the 
hepatocytes into the sinusoid, (8) bile transport into the duodenum. 
Several drugs are secreted by the liver into bile and are therefore 
capable of undergoing EHC. These include antibiotics, nonsteroidal anti- 
inflammatory drug (NSAIDs), hormones, opioids, digoxin, and warfarin 
(Gao et al., 2014; Malik et al., 2016; Roberts et al., 2002). The impact that 
EHC has on the PK and pharmacodynamics (PD) of a drug depends on: 
(a) the importance of biliary excretion of the compound relative to renal 
and metabolic clearance processes; and (b) the efficiency of gastroin-
testinal absorption (i.e. permeability) of the drug. Of particular impor-
tance is the potential amplifying effect of EHC on PK and exposure 
variability of a given compound (Roberts et al., 2002). High PK vari-
ability due to EHC has been reported for many compounds such as 
mycophenolate mofetil, ezetimibe, regorafenib, estrogen and steroids 
(Adlercreutz et al., 1979; Bullingham et al., 1998; Keunecke et al., 2020; 
Kosoglou et al., 2005; Sher and Rahman, 2000). The effect that EHC can 
have on PK variability was shown for regorafenib using population PK 
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modeling (Keunecke et al., 2020). Only by incorporating EHC in the 
model as well as time and frequency of food intake was the model able to 
accurately describe the PK profile from clinical studies. Other covariates 
had only a minimal effect on describing the overall variability in the 
exposure. This model was useful in estimating the individual patient’s 
exposure to regorafenib, which is becoming increasingly important in 
the growing application of precision medicine and flexible dosing to 
optimize clinical benefit. Ezetimibe is another drug known to undergo 
significant EHC (Kosoglou et al., 2005), which results in multiple peaks 
and significant interindividual variability (46% - 80%). It was conclu-
sively demonstrated through population PK modeling that incorporation 
of EHC and food intake in the model accurately described the observed 
variability (Ezzet et al., 2001). 
Biliary clearance is determined by the unbound fraction in blood, 
metabolic intrinsic clearance, flow rate and convection/mixing of liver 
blood, hepatocyte permeability and surface area, and drug concentra-
tion (Fagerholm, 2008). Biliary clearance is also determined by the 
stability of drugs and phase II metabolites in bile and intestinal fluids, 
permeability across the bile duct epithelium and intestinal wall, and 
flow rate of bile and intestinal contents. Additionally, highly permeable 
compounds excreted into the intestine via bile are expected to be more 
rapidly and extensively absorbed than low permeability compounds, 
and consequently will have more distinct EHC. Several other factors 
have also been shown to impact the extent of EHC, including the bio-
logical influences of species variation, sex differences, age and devel-
opmental stage, nutritional status, disease states, and drug-drug 
interactions (DDI). DDI can affect the production of polar metabolites by 
cytochrome P450 (CYP) enzymes, conjugation, transporters, intestinal 
transit time and bioavailability. Associated with such drug interactions 
is interindividual variability in the inhibition and induction of enzymes, 
with varying degrees of effect on EHC (Malik et al., 2016; Roberts et al., 
2002). 
For drugs undergoing biliary excretion, EHC represents a secondary 
absorption phase for the drug. From a PK perspective, therefore, EHC 
can prolong the elimination half-life (t½), increase AUC (bioavailability), 
and may also produce multiple peaks in the plasma concentration-time 
profile of a drug (Gao et al., 2014; Malik et al., 2016; Roberts et al., 2002) 
(Figure 8). The typical multiple peak plasma concentration vs time 
profile is demonstrated for low metabolic clearance compounds, with 
efflux, moderate-to-high intestinal permeability and moderate-to-high 
fraction absorbed. 
The clinical significance of EHC depends on the pharmacological 
and/or toxicological properties of the biliary excretory products, their 
availability for absorption, and whether the absorbed products are re- 
extracted by the liver or pass into the general circulation (Malik et al., 
2016; Roberts et al., 2002). In some cases, EHC may be a therapeutic 
advantage due to sustained exposure achieved by the recirculation. On 
the other hand, it is also possible that EHC can lead to toxicity due to 
increased exposure and/or increase elimination half-life. In cases of 
acute drug toxicities, activated charcoal is a commonly used treatment 
because of its ability to adsorb materials with a high capacity. Although 
timely single-dose administration is effective in preventing drug ab-
sorption of orally ingested drugs, repeated doses of activated charcoal 
have been shown to increase drug clearance, resulting in reduced plasma 
exposure of drug. This is the result of decreased enterohepatic recycling 
and increased drug exsorption from the intestine (Figure 8). 
Due to the potential significant impact on PK and PD of a drug, 
several efforts to accurately model EHC and its effect on PK has been 
explored. EHC has been described by classical compartmental models. 
These models include two or three compartments describing the trans-
port of the drug from the central compartment to the gut and one 
compartment for the gall bladder. Recirculation loops of more than one 
compartment allowed a better simulation of the delay caused by the 
recirculation process. Such models have been successfully applied to 
describe EHC in preclinical species such as rats which do not have a gall 
bladder (Ouellet and Pollack, 1995; Pollack and Brouwer, 1991). They 
are not appropriate to describe the discontinuity in the enterohepatic 
cycling process caused by gallbladder emptying. EHC models that ac-
count for the effect of gall bladder emptying can further be classified in 
models where emptying is assumed to occur at regular intervals and 
models with irregular emptying times. Models based on irregular 
lag-time intervals are closer to physiological reality since gall bladder 
emptying starts when food begins to be digested. Furthermore, the 
extent of biliary emptying may depend on the quantity of fat in the meal. 
But these models are mathematically more complex (Plusquellec and 
Houin, 1992). Physiologically based PK modeling (PBPK) has also been 
explored in describing EHC. For example, PBPK has been used to suc-
cessfully model the bile appearance of glycyrrhizic acid and its metab-
olites after intra-peritoneal administration (Ploeger et al., 2000). A 
similar whole-body PBPK model using in vitro hepatocytes was devel-
oped to characterize the hepatic transport of repaglinide and to predict 
its PK and DDI (Varma et al., 2013). 
2.3. Colonic phase 
2.3.1. Colonic transit times 
The transfer of dissolved and undissolved drug material as well as of 
oral drug product through the colon depends on various factors, which 
are either formulation-related (e.g. size, shape and surface properties), 
related to the characteristics of the luminal contents (e.g. osmolarity and 
viscosity) or related to the individual’s physiology (e.g. age, sex differ-
ences, body position, circadian rhythm) and dietary habits (time and 
composition of the last meal). 
In a recent meta-analysis published by Abuhelwa and colleagues, 
meta-means of 20.28 h and 31.95 h were given for the colon transit 
times (CTT) of tablets and pellets, respectively (Abuhelwa et al., 2016). 
The longer CTT observed for multiple-unit dosage forms such as pellets 
as compared to monolithic objects is typically explained by trapping of 
smaller particles in the haustra of the colon. Therefore, larger objects 
typically move faster through the colon. 
The same techniques used for measurement of SITT, can also be used 
to study CTT: scintigraphy, magnetic marker monitoring, MRI, tele-
metric capsules and radiopaque markers (Hens et al., 2017). In a 
SmartPill® study with 215 healthy volunteers, Wang and colleagues 
reported a mean CTT of 23.1 h, but the 5th and 95th percentiles had 
values of 3.4 h and 50.5 h, respectively. These data demonstrate that the 
colon transit time can be extremely variable. Similar results were 
Fig. 8. Plasma levels of estriol after oral administration of estriol 12 mg 
without and with 20 g of activated charcoal. Figure reproduced from Roberts 
et al., 2002, with permission. 
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obtained in a recent SmartPill® study with 19 young and healthy vol-
unteers, where the colon transit time was found to range between 2 h 
and more than 40 h (Koziolek et al., 2015b). Since the object was the 
same for all volunteers, the variability could only be caused by the in-
dividual GI physiology as well as the dietary habits of the subjects. 
Favorable conditions for drug release and absorption are mainly 
present in the ascending colon since sufficient volumes of free fluid can 
only be found in this part of the colon. Hence, pharmaceutical scientists 
are particularly interested in assessing regional transit times through 
ascending, transverse and descending colon (Abrahamsson et al., 1996). 
Several in vivo studies have shown that there are large inter- and intra-
individual variations in terms of transit times through the different 
segments of the colon. In Figure 9, the intraindividual variability in 
transit through the intestines is shown for one subject who repeated the 
same magnetic marker monitoring experiment on five occasions. 
In a study by Watts and colleagues, mean residence times of 8.4 mm 
tablets in the ascending colon were in the range of 3.50 – 15.75 h. For 
small resin pellets, the same range was measured (Watts et al., 1992). 
This large variation can be explained by the fact that the transfer 
through these regions is mainly controlled by propulsive mass move-
ments. These occur infrequently several times a day (Bassotti et al., 
1995). Thereby, luminal material can be transported over distances of 
up to 50% of the colon length within short periods of time. By use of 
magnetic marker monitoring, it was nicely illustrated that it can take 
less than 2 min to push a small particle of 1 mm through the entire 
ascending and transverse colon (Weitschies et al., 2010). In case of an 
extended release formulation, for which colonic drug absorption plays 
an important role, an early mass movement event may limit drug ab-
sorption (Wilson and Washington, 1988; Xu et al., 2018). Additionally, 
the mass movement in the colon initiates the entry of material from the 
ileum into the caecum. By this, it may terminate the absorption of drugs 
incompletely absorbed in the small intestine as has been noted for 
gefitinib (Wilson et al., 2009). 
Despite its relevance, the effect of variable CTT on drug absorption of 
orally administered drugs is not well studied. It is expected that short 
CTT have a negative impact on the processes of dissolution and/or ab-
sorption, particularly for modified-release formulations such as colon- 
targeted formulations or extended-release formulations. To assess how 
the variability in CTT affects the PK profile, combined imaging (e.g. 
MRI) and PK studies can provide better understanding. 
2.3.2. Variability of luminal composition in distal ileum and proximal colon 
Variability of lower intestinal contents can have an impact on the 
performance of advanced formulations (extended release or colon- 
targeting), or for drugs with incomplete small intestinal absorption. 
Based on data from a limited number of individuals, in the distal 
ileum, pH values range from 7 to 8.7 (median pH 8.1), regardless of the 
dosing conditions (Reppas et al., 2015). In the fasted state, a median 
value of 7.8 and a range between 6.2–8.5 have been reported both for 
the cecum and the ascending colon (Diakidou et al., 2009c; Reppas et al., 
2015). A similar degree of variability has been observed in the fed state 
but in this case pH values varied between 5.3–7.9 and the median pH 
was lower, about 6, presumably due to the increased bacterial fermen-
tation activity, after meal consumption (Koziolek et al., 2015a). Varia-
tions of colonic pH could be expected to impact colon-targeted 
formulations based on pH-sensitive polymers. 
A number of other characteristics of colonic contents (buffer capacity 
and osmolality; total short chain fatty acid, protein and carbohydrate 
concentrations) also show significant inter-individual variation, as 
recently described in an UNGAP review (Vertzoni et al., 2019). 
The described variability of the composition of colonic contents re-
sults in a dramatic variability of drug solubility in colonic fluids, espe-
cially in the fed state (Figure S1 in the Supporting information). As 
solubility sets the upper limit of intracolonic drug concentration, it could 
in turn impact drug absorption from the lower intestine (Tannergren 
et al., 2009). Despite the high variability, higher solubility values were 
observed in the colonic aspirates than would be predicted from plain 
buffers at the equivalent pH values (Vertzoni et al., 2010). This obser-
vation has been attributed to the presence of bile acids, PC, and FFA at 
total concentration of about 1 mM (see Table S3 in the Supporting in-
formation) and, perhaps, peptides/proteins that are present in the 
ascending colon and could solubilize drugs (Vertzoni et al., 2010). 
2.3.3. The microbiome 
Trillions of bacteria, bacteriophages, fungi, protozoa and viruses 
known collectively as the microbiota inhabit the human GIT. Although 
commonly used interchangeably, the term ‘microbiota’ refers to a pop-
ulation of microbes, and ‘microbiome’ encompasses the genomes and 
functions of the microbes. The broad metabolic capacity of gut micro-
biota has been implicated in drug pharmacokinetics for several decades 
however the true scale of microbiota-drug interactions in the GIT has 
Fig. 9. Gastrointestinal transit of magnetically marked non-disintegrating capsules in the same volunteer after ingestion with 150 mL of water. (Capsule intake after 
8 h fasting, in the experiments 1–4 lunch was served 240 min after ingestion). Reprinted from (Weitschies et al., 2005), Copyright (2005), with permission 
from Elsevier. 
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only emerged recently (Figure 10)(Clarke et al., 2019; Collins and Pat-
terson, 2020; Scheline, 1968; Tian et al., 2020). 
In the early 2000s Astra Zeneca developed an in vitro colonic model 
and found 19 out of 51 drugs analysed to be significantly altered in the 
presence of microbiota. A few years later just over 30 drugs were known 
to be metabolised by gut microbiota, however at the time this number 
was estimated as being just the tip of the iceberg (Sousa et al., 2008). 
Advances in genetic sequencing in following years facilitated the Human 
Microbiome Project in 2012, which for the first time characterised 
bacteria inhibiting the GIT at the genomic level (Huttenhower et al., 
2012). Once the species of bacteria inhabiting the gut were known, then 
seminal work mapping reactions between bacteria and drugs followed 
(Javdan et al., 2020; Zimmermann et al., 2019a; Zimmermann et al., 
2019b). Over 270 drugs are now recognised as being susceptible to 
direct metabolism by gut bacteria, yielding inactive, more active, or 
even toxic metabolites (Coombes et al., 2020; Enright et al., 2016; Yadav 
et al., 2013). As microbiome composition is as unique as one’s finger-
print, it is highly likely that microbiota drug metabolism will vary be-
tween individuals (Franzosa et al., 2015). Age, diet, medication use, and 
lifestyle are all important determinants of an individual’s microbiome 
(Asnicar et al., 2021; Chaudhari et al., 2020; Keohane et al., 2020; Maier 
et al., 2018). 
Intestinal microbiota are capable of altering pharmacokinetics no 
matter the route of drug administration. Orally administered drugs will 
encounter increasing concentrations of microbiota whilst passing down 
the GIT, making them vulnerable to reaction with microbial enzymes 
(James et al., 2020). Even drugs rapidly absorbed in the upper GIT, 
where microbial density is typically lower, are known to undergo 
microbiota metabolism (Maini Rekdal et al., 2019). Drugs administered 
parenterally may interact with intestinal microbiota through excretion 
in bile or contact with the GI epithelium during systemic circulation 
(Enright et al., 2018; Enright et al., 2017). Whilst direct alteration of 
drug structure by bacterial enzymes is the most characterised mode of 
microbiome-mediated drug metabolism, hepatic metabolism of drugs 
can also be indirectly altered by intestinal microbiota (Walsh et al., 
2020). Metabolites produced by gut microbiota can diffuse over the GI 
epithelium and reach the liver via its portal vein. There, they can alter 
the hepatic transcriptome and thus the expression of CYP450 enzymes or 
drug transporters (Bjorkholm et al., 2009; Ishii et al., 2012; Kuno et al., 
2016). Gut microbiota can also indirectly affect the absorption and 
pharmacokinetics of drugs through impacts on key GI parameters such 
as pH, bile acid concentration and composition, motility, and epithelial 
drug transporter expression (Ghyselinck et al., 2020; Mayeur et al., 2013; 
Pavlovic et al., 2018; Roager et al., 2016; Yuan et al., 2020). 
Activation of drugs by the gut microbiome. The first identification of 
microbiota drug activation was in the 1930s when Prontosil, an early 
sulfonamide antibiotic, was observed to have no activity in vitro (Fuller, 
1937). It was subsequently revealed that bacterial azoreductases in the 
gut are able to cleave Prontosil into its active form, sulfanilamide 
(Sharma et al., 2019). This discovery sparked the development of a 
number of other prodrugs with reactive azo bonds, such as sulfasalazine, 
balsalazide, and olsalazine (Cooke, 1969; Sousa et al., 2014). These 
prodrugs are known to undergo a similar azo reduction as Prontosil, 
liberating the active anti-inflammatory 5-aminosalicyclic acid for local 
treatment of colitis. Due to age-associated changes of the gut microbiota, 
elderly patients may have different biotransformation profiles of pro-
drugs such as sulfasalazine (Merchant et al., 2016). Indeed, one study 
has shown that the elimination half-life of sulfasalazine and steady state 
serum concentration of its metabolite N-acetyl-5-acetylsalicyclic acid 
Fig. 10. Overview of drug metabolism throughout the host and the gut microbiome [adapted from (Chae et al., 2020) and reproduced with permission from 
the publisher]. 
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are greater in old age (Taggart et al., 1992). Lactulose, an osmotic 
laxative, is activated by colonic bacterial deglycosylation to lactic and 
acetic acids (Kim, 2015). These acids effectively trap ammonia in the 
colon, preventing its diffusion into circulation and lowering the risk of 
hepatic encephalopathy. A second laxative, sodium picosulfate, is 
transformed into its active form by caecal bacteria (Kim et al., 1992). 
Bacteria in the caecum are similarly involved in the activation of 
loperamide oxide through an N-oxide reduction reaction (Lavrijsen 
et al., 1995). Once activated, loperamide acts as a local opioid receptor 
agonist, helping to decrease gut motility and relieve diarrhoea symp-
toms. The presence of the right strains and concentrations of metabo-
lising bacteria is vital for these prodrugs’ activities. Enzymes produced 
by intestinal bacteria can be highly strain specific, and thus individual 
ability to activate prodrugs may vary due to differing microbiota com-
positions (Koppel et al., 2018). 
Inactivation of drugs by the gut microbiome. Inactivation of a drug in the 
GIT can decrease diffusion of the active compound into systemic circu-
lation, thus impairing therapeutic action. Significant variability of pa-
tient’s gut microbiota is known to impact the pharmacokinetics of 
multiple drugs. The cardiac glycoside digoxin is a longstanding example 
of bacterial inactivation in the GIT. Certain strains of colonic actino-
bacterium Eggerthella lenta are known to reduce digoxin’s lactone ring, 
and thus increase dose requirements of the drug (Saha et al., 1983). 
Recently, the metabolising enzyme produced by E. lenta has been 
identified as ‘Cgr2’, a novel flavoprotein reductase (Koppel et al., 2018). 
Strains of E. lenta capable of producing Cgr2 are thought to be present in 
the guts of over 40% of the global population in varying abundance 
(Koppel et al., 2018). Patients with higher concentrations of metabo-
lising E. lenta may therefore be at risk of underdosing. To add another 
layer of variability, it has also been found that protein-rich diets can 
impair the actions of E. lenta, as the amino acid arginine is a natural 
inhibiter (Haiser et al., 2013). A second case of bacterial reduction 
resulting in drug inactivation can be exemplified by the histamine 2 
receptor antagonists ranitidine and nizatidine. N-oxide reduction of 
these drugs in colonic conditions results in inactive metabolites; possibly 
explaining the poor bioavailability of ranitidine in the large intestine 
(Basit et al., 2002). Interestingly, cimetidine and famotidine, also his-
tamine 2 receptor antagonists, are not seen to be bacterially degraded. 
The amino acid L-DOPA is a key component of Parkinson’s disease 
management, and another prime example of gut bacteria inactivation. 
Premature conversion of L-DOPA to dopamine in the jejunum by the 
bacterial enzyme tyrosine decarboxylase is known to increase patients’ 
L-DOPA dose requirements (van Kessel et al., 2019). Genes encoding 
tyrosine decarboxylase have been found in the genomes of several spe-
cies of Lactobacillus and Enterococcus (Zhu et al., 2016). Variability in 
patient’s disease severity and PK can often make finding the right dose of 
L-DOPA a difficult and fluctuating process. As conversion of L-DOPA to 
dopamine should ideally occur in the brain for therapeutic action, this 
intestinal inactivation has prompted an increased interest in identifying 
selective inhibitors of bacterial tyrosine decarboxylase (Lam et al., 
2019). 
Gut microbiome-mediated drug toxicity. Toxicity can be a grave outcome 
of microbiota-mediated drug metabolism. The most infamous example is 
undoubtedly sorivudine, which led to the death of 18 patients in Japan, 
only 40 days after its brief approval for market in 1993 (Okuda et al., 
1998). The antiviral was unknown to interact with the 5-fluorouracil 
(5-FU) prodrug, tegafur, through a microbially-mediated mechanism. 
Intestinal microbiota hydrolyse sorivudine to bromovinyluracil in the 
caecum and colon. Bromovinyluracil is then metabolised by the host to 
an inhibitor of dihydropyrimidine dehydrogenase, which is necessary 
for breakdown of 5-FU (Nakayama et al., 1997). Tragically, patients 
coadministered sorivudine and tegafur experienced accumulation of 
5-FU, which culminated in pancytopenia, bloody diarrhoea, severe 
anorexia, and ultimately, death (Okuda et al., 1998). Sorivudine was 
withdrawn from the market a few weeks later, and highlights the 
importance of studying drugs’ microbial reactions prior to clinical use 
(McCoubrey et al., 2021). Bacterial metabolism of the antineoplastic 
agent irinotecan is another example of microbiome-mediated toxicity. 
β-glucuronidases produced by colonic bacteria deconjugate 
glucuronide-conjugated irinotecan in bile, leading to severe 
dose-limiting diarrhoea (Wilson and Nicholson, 2017). Administration 
of antibiotics in rats concurrently dosed with irinotecan has shown 
significantly decreased β-glucuronidase activity and reduced intestinal 
damage (Takasuna et al., 1996). As broad-spectrum antibiotics are not 
an ideal solution to this problem, there has been much focus on devel-
oping specific β-glucuronidase inhibitors; this has been relatively com-
plex owing to nuances in β-glucuronidases produced by different 
bacterial strains (Wilson and Nicholson, 2017). 
Impact of microbiome variability on bacterial drug degradation in the lower 
intestine. Gut microbiome variability on bacterial drug degradation in 
the lower intestine has been studied ex vivo by using two chemically 
stable compounds, metronidazole (a nitroreductase substrate) and 
olsalazine (an azoreductase substrate)(Karatza et al., 2017). Interindi-
vidual variability of drug degradation rates was very high in all cases, 
with lowest variability observed for the data for olsalazine in the con-
tents of distal ileum collected in the fed state (Figures S2 and S3 in the 
Supporting information). While olsalazine was found to be practically 
stable in the contents of distal ileum, its degradation characteristics in 
the cecum were similar to those in the entire ascending colon (Vertzoni 
et al., 2011). 
Based on metronidazole and olsalazine data (Figures S2 and S3 in the 
Supporting information), the average nitroreductase and azoreductase 
activity in the fasted state appears to increase when switching from the 
distal ileum to the cecum. This is in line with observations showing that 
nitroreductase activity increases from the proximal to the distal colon 
(McBain and Macfarlane, 1998). In comparison with the fasted state, 
regional (e.g. distal ileum vs. caecum) differences in degradation appear 
to be small or negligible in the fed state, presumably because food res-
idues decrease bacterial degradation via a competitive inhibition 
mechanism. For both metronidazole and olsalazine, the degradation rate 
constant in the fasted state was higher in the cecum than in the distal 
ileum (Karatza et al., 2017). 
3. Effect of formulation on dosing and PK profile variability 
In general, in an industrial setting where patient-centric develop-
ment is applied, formulation-induced variability of PK parameters (Cmax, 
tmax, AUC) will be kept to an absolute minimum by design. More spe-
cifically, via formulation screening and robustness studies, the impact of 
the formulation on the release kinetics will be characterized and kept 
within a predefined formulation design space in which no impact on the 
in vivo release and PK profile is expected. This approach should also 
guarantee a similar pharmacological response across the entire patient 
population. Especially for drugs that have a narrow therapeutic margin, 
excessive inter- and intra-individual variability in exposure can directly 
lead to safety or efficacy issues. This implicates that formulations should 
be robust enough to cope with the numerous potential sources of vari-
able absorption as described in previous paragraphs. 
Already in 1996, Hellriegel et al. highlighted the inverse relationship 
between absolute bioavailability and interindividual variability (Hell-
riegel et al., 1996). This relationship is one of the important drivers for 
development efforts to increase the bioavailability and as such decrease 
the variability in exposure. This principle has major consequences in the 
current drug development landscape where a significant proportion of 
the newly discovered drugs are poorly soluble and hence prone to 
limited absorption and bioavailability, significant food effects and high 
variability. The continuous effort to enhance bioavailability comprises a 
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multitude of formulation techniques that have been reviewed exten-
sively in the past (Williams et al., 2013). Finally, all development efforts 
need to result in a drug product that is compliant with the target product 
profile listing the required product characteristics to assure efficacy, 
safety and compliance towards the targeted patient population (e.g. 
acceptable pill burden, food label and restrictions, dosage strength 
range). 
In this section, typical formulation characteristics are described that 
could contribute to in vivo variability, as well as potential mitigations to 
reduce the variability. A few cases are included to illustrate the impact of 
formulation approaches on variability of exposure, observed with highly 
lipophilic drugs. Some of the physicochemical and biopharmaceutical 
properties of the example drugs, including their solubility in biorelevant 
media such as fasted state simulated gastric fluid (FaSSGF), fasted state 
simulated intestinal fluids (FaSSIF-v1) and fed state simulated intestinal 
fluids (FeSSIF-v1) are presented in Table 3. 
3.1. Solid state of the active ingredient 
As the in vivo release and exposure is related to the gastrointestinal 
dissolution rate, the administration of a compound as a solution (con-
taining the compound without its crystal lattice) could eliminate 
dissolution as a potential variability factor, provided that gastrointes-
tinal precipitation after intake does not occur or can be controlled (e.g. 
via a precipitation inhibitor added to the solution). Therefore, a solution 
can be considered during drug product development as a low PK vari-
ability reference compared to a solid including the crystalline form of 
the compound. An additional option to pursue lower PK variability via a 
solid state change is the administration of the amorphous form of the 
active ingredient as a solid dispersion. Similar to a solution, auxiliary 
agents in the form of polymers that improve supersaturation and inhibit 
precipitation could be needed (e.g. various types of hydroxypropyl 
methylcellulose (HPMC)). In general, the improvement in dissolution 
and solubility characteristics associated with amorphous solid disper-
sions goes hand in hand with enhanced bioavailability and a lower 
variability of PK parameters. 
A case (Compound A) is discussed in which the variability in expo-
sure between an oral solid formulation containing crystalline drug and a 
solution is compared. Compound A is a BCS class 2 compound and a 
weak base for which the solubility in simulated gastric fluids is more 
than 1000-fold higher than in simulated intestinal fluids of the fasted 
state (Table 3). To evaluate the absorption potential of a micro-
suspension of compound A, a relative bioavailability study was per-
formed in which the microsuspension was studied in cross-over 
comparison with a cyclodextrin (CD)-based solution. Despite its high 
solubility in the stomach and good permeability properties, the overall 
exposure when using the microsuspension under fasted state conditions 
was low (more than 10-fold lower compared to the CD solution). 
Moreover, variability both in AUC and Cmax was 2-fold and 3-fold 
higher, respectively, than for the CD solution (Table 4). CDs have 
been reported to inhibit supersaturation (Brewster et al., 2008) and this 
might explain why the supersaturation which is induced upon GI 
transfer and which is inherently metastable in nature does not result in 
larger variability in the PK for the CD solutions. The PK profile obtained 
with the CD solution was subsequently used as a target profile for new 
formulation candidates. 
This case is well in accordance with the observation by Hellriegel 
et al. that improvement of oral bioavailability usually goes hand in hand 
with an improvement in the inter- and intraindividual variability 
(Hellriegel et al., 1996). 
3.2. Particle size distribution of the active ingredient 
Next to the solid state, another factor that could impact the disso-
lution rate is the particle size distribution of the active ingredient. 
Especially for BCS class 2 or 4 compounds, the formulation should be 
sufficiently robust to keep the particle size range within predefined 
limits. Therefore, typically, specifications will be defined to monitor the 
particle size distribution of the active ingredient during and after 
completion of manufacturing, as well as upon stability. Discriminative in 
vitro dissolution techniques are often applied as an indirect control for 
potential particle size changes of the active ingredient in the drug 
product. The following case study (compound B) illustrates the impact of 
particle size on variability in exposure. 
Compound B is a neutral weakly acidic BCS class 2 compound with a 
very low aqueous solubility of 1 µg/mL and a high permeability 
(Table 3). In support of the development of an oral solid dosage form, 
the impact of particle size on dissolution rate and exposure was evalu-
ated. The drug was milled to subfractions with a median particle size by 
volume (Dv50) of 6 and 25 µm and the dissolution behaviour of capsules 
containing the milled drug was evaluated in fasted state simulated in-
testinal fluids (FaSSIF-v1, pH 6.5), see Figure S4 in the Supporting in-
formation. The capsules containing drug milled to Dv50 = 6 µm showed a 
significantly faster dissolution rate as compared to the coarser material 
with Dv50 = 25 µm. To evaluate the in vivo impact of this observed in 
vitro difference in dissolution rate, the capsules were dosed to dogs and 
the plasma concentrations were followed up to 24 hours after dosing. As 
can be observed in Table 5 the average exposure was not affected by the 
difference in particle size. 
The variability in exposure, however, was much higher for the cap-
sules containing the larger particles than for the capsules containing the 
smaller particles. The CV % on AUC and Cmax upon dosing the coarser 
particles were almost 5-fold and 3-fold higher, respectively than 
observed for the smaller particles. The more variable absorption is also 
reflected by the tmax, which is consistent for the drug milled to 
Dv50 = 6 µm and highly variable for the material milled to Dv50 = 25 µm. 
3.3. Interplay pKa and gastro-intestinal pH variability 
A parameter affecting the in vivo solubilization of the compound in 
the GIT is the dissociation constant, usually expressed as pKa. As illus-
trated by the Henderson-Hasselbalch equation, weak bases will typically 
show higher solubility in the acidic environment of the fasted stomach 
and can precipitate upon transfer to the duodenum and lower intestine 
with typically higher pH values. Weak acids generally demonstrate the 
Table 3 
Physicochemical and biopharmaceutical characteristics of compounds A, B and 
C.  
Characteristic Compound A Compound B Compound C 






Lipophilicity LogP = 2.95 LogD7.4 = 3.59 LogP = 5.20 
Biorelevant solubility 
(mg/ml)    
FaSSGF 2.17 0.001 BLoQ 
FaSSIF-v1 0.002 0.002 0.008 
FeSSIF-v1 0.021 0.028 0.019 
Aqueous solubility 
(mg/ml)     
0.298 (pH = 2) 0.001 (pH = 1) BLoQ (pH = 3)  
0.003 (pH = 4) 0.001 (pH = 4) 0.003 (pH = 5)  
<0.001 
(pH = 8) 
0.001 (pH = 7.4) 3.22 (pH = 7) 
BLoQ=Below Limit of Quantification. 
Table 4 
Coefficient of variation on the geometric means of Cmax and AUCinf for formu-
lations of Compound A.  
Formulation type CV % on Cmax CV % on AUCinf 
microsuspension 52.5 59.6 
CD solution 18.4 33  
Z. Vinarov et al.                                                                                                                                                                                                                                 
European Journal of Pharmaceutical Sciences 162 (2021) 105812
17
opposite behaviour with lower solubility in the acidic stomach and 
higher solubility in intestinal environment. For these compounds, (weak 
bases or weak acids), variations in stomach pH and/or co-medication 
with gastroprotective drugs such as PPIs or histamine 2 receptor an-
tagonists could contribute to the overall PK variability (both inter- and 
intraindividual). For example, upon administration of a weak base, an 
acidic stomach contributes to solubilization in the stomach and super-
saturation upon GI transfer, driving a higher compound concentration 
gradient, absorption and exposure throughout the GIT. However, an 
increase of the stomach pH (as a natural physiological variation or 
caused by PPI intake) will lower stomach solubilization and supersatu-
ration upon GI transfer and cause lower downstream absorption. Both 
drug substance and drug product related aspects including the intestinal 
permeability of the compound, the dose and the presence of a precipi-
tation inhibitor, can impact supersaturation/precipitation behaviour of 
a weak base upon GI transfer. 
Also for weak acids, the reported intra- and interindividual varia-
tions in GI pH can result in variable exposure (Abuhelwa et al., 2016; 
Clarysse et al., 2009b). Formulation approaches that lower the sensi-
tivity of the solubility to the pH for a certain dose can therefore posi-
tively impact the variability in PK as exemplified in the below case study 
(Compound C). 
For compound C, a weak acid with a pKa of 4.4, the solubility of the 
most stable crystalline form is low and highly sensitive to pH changes 
(Table 3). Figure 11 shows the dissolution profiles of the crystalline 
material in FaSSIF at pH values ranging from 5 to 7. The fraction of the 
dose dissolved was low in FaSSIF at all three pH values tested and the 
relative difference in the dissolution plateau was significant along the 
pH range tested. A 6-fold increase in dissolution plateau was observed 
between pH 5 and pH 7 and between pH 6.5 and 7, still a significant 
increase in the dissolution plateau of around 50% was measured. In 
contrast, when the drug was introduced as amorphous material, close to 
complete dissolution of the dose was observed in FaSSIF with a pH 
ranging from 5.7 to 6.8 resulting in dissolution behaviour that is much 
less sensitive to the inter and intraindividual pH variability that is 
inherent to the GI environment. 
Other specific cases of compounds with PK profiles that are sensitive 
to PPI intake are described in section 4 (patients on PPI). 
3.4. Interplay between enteric polymers and gastro-intestinal pH 
variability 
Polymers that are added to the formulation as an auxiliary agent to 
reduce in vivo precipitation and/or stabilize amorphous dispersion (e.g. 
hydroxypropyl methylcellulose phthalate (HPMCP) or hydroxypropyl 
methylcellulose acetate succinate (HPMC-AS)) may equally cause vari-
ation in release and absorption if they contain chemical groups with a 
pKa in the pH range that’s relevant for the GIT. For example, hydrated 
tablets containing HPMCP will swell between pH 4 and 6 (Xu et al., 
2003) and release compound in this range. Also for different grades of 
HPMC-AS (referring to differences in substitution extents of mainly 
acetyl and succinoyl groups), differences in dissolution properties have 
been reported in function of pH (Sakuma et al., 2009). 
Therefore, variation in pH along the GIT could cause variation in 
release in specific intestinal parts linked to the absorption window. 
Figure 12 shows the meta-means and the meta-standard deviations of 
the pH along the GIT as reported by Abuhelwa et al. (Abuhelwa et al., 
2016). A comparison of the GI pH ranges with the pH values at which the 
different HPMC-AS grades start to dissolve exemplifies how variability 
in the GIT can lead to variation in release profile of drugs from formu-
lations containing these types of polymer. 
Table 5 
Pharmacokinetic parameters derived from the plasma profiles of dogs that were 
dosed Compound B milled to Dv50 = 6 µm or 25 µm.   
Capsule, 2 mg, Dv50 ¼ 6 
µm 
Capsule, 2 mg, Dv50 ¼ 25 
µm 
Cmax (ng/mL) 24.7 ± 3.96 18.7 ± 8.97 
tmax (h) 2.00 (2.00 - 2.00) 7.00 (2.00 - 7.00) 
AUC0–24 (ng•h/ 
mL) 
129 ± 11.8 123 ± 55.9  
Fig. 11. Dissolution of crystalline and amorphous drug in fasted state simulated intestinal fluids, buffered at different pH values. Mass to volume ratio of the 
dissolution experiment was 333 µg/ml. 
Fig. 12. Illustration of the pH at which the different HPMC-AS grades start to 
dissolve (dotted lines) in view of the reported meta-means and meta-standard 
deviations of the pH in the different parts of the gastrointestinal tract (fil-
led circles). 
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4. Variability in specific populations and patients with chronic 
conditions 
Even in a healthy population, there exists a significant variation in 
GIT physiology related to age (pediatrics, geriatrics), or sex (male vs. 
female). On top of that, a variety of diseases impact the GIT, which can 
also cause significant variability in oral drug absorption and, conse-
quently, compromise drug safety and efficacy. These aspects of vari-
ability and their implicit or explicit effect on drug absorption are 
reviewed in the current section. 
However, it should be noted that due to limited (in most cases) ev-
idence, the question whether the observed variability is even stronger 
due to the underlying physiological or pathological differences, remains 
unclear. Still, the presented information can be used to initiate a dis-
cussion on this unexplored topic and can serve as a starting point to 
conceive much needed clinical studies that are required to gather data 
with good statistical quality: an indispensable tool in the study of the 
variability problem. 
4.1. Ageing and sex effects 
4.1.1. Pediatrics 
Children commonly need flexible formulations, with a shift from 
liquids to solid forms (mini-tablets, multiparticulates, orodispersibles) 
(Thabet et al., 2018). The different formulations further add to the 
maturation driven variability of absorption, as maturation is the key 
source of variability in pediatrics, most pronounced in early infancy 
(van den Anker et al., 2018). During maturation, body weight, organ size 
and function alter, as does body composition, protein expression and 
cellular functions (Stillhart et al., 2020). These maturational changes 
also relate to GI physiology. 
Over the first years of life, there are changes in gastric pH by 
maturational parietal cell density and function (Kelly and Newell, 
1994). A neutral gastric pH observed at birth is consistently reported. In 
contrast, there is debate on the maturational changes in gastric acid 
production and pH throughout childhood (van den Anker et al., 2018). 
Some suggest that this pattern starts with a neutral gastric pH in the first 
days of life, followed by a progressive decrease over weeks to years to 
reach adult values. Others suggest that an acidic gastric pH is present 
from neonatal life onwards (Batchelor et al., 2014; Mooij et al., 2012). A 
neutral pH at birth facilitates absorption of macromolecules from 
colostrum (Smits et al., 2013). Furthermore, the gastric pH in early in-
fancy is likely affected by the frequency and volume of milk ingested, as 
this also displays maturational changes (Yeung et al., 2020). The gastric 
fluid composition (osmolarity, bile salts) also displays age-dependent 
changes (Van Den Abeele et al., 2018). 
The gastric pH matters for drug absorption: a higher pH results in 
increased oral bioavailability of acid-labile drugs (like beta-lactam an-
tibiotics) due to decreased degradation. For weak organic acids with a 
narrow therapeutic index (like phenytoin), developmental pH may 
result in frequent dose adjustments to maintain target exposure (Smits 
et al., 2013). 
Gastric emptying is another example of the merged effects of matu-
ration, feeding practices and diet. Gastric emptying is slower in (pre) 
term infants, reflected by e.g. paracetamol absorption (Bonner et al., 
2015). In a meta-analysis, meal type (aqueous>breast milk>formula 
milk>semi-solid>solid) was the main driver of gastric emptying (Bon-
ner et al., 2015). The formula type (extensively hydrolysed>partially 
hydrolysed>intact protein formula) further affects gastric emptying 
(Staelens et al., 2008). The SITT in healthy children is likely not affected 
by age, although PBPK modeling was only explored with theophylline as 
model compound in children (8–14 years), while being slower in neo-
nates and infants (Bonner et al., 2015; Maharaj and Edginton, 2016). For 
the colonic transit time, a mean value of 40 hours (4–15 years) is sug-
gested, compared to adult values of 20 h and 32 h for tablets and pellets 
(Abuhelwa et al., 2016; Wagener et al., 2004). 
Pancreatic enzymes like lipase are low at birth to evolve over infancy 
(McClean and Weaver, 1993). However, this is somewhat compensated 
by lipase activity in human milk (Li et al., 2007). The bile acid pool size, 
bile flow and its ileal reabsorption also display maturation, resulting in 
lower duodenal bile acid concentrations (Nicolas et al., 2017). Such 
data, when combined with volumes, are relevant covariates of 
age-related changes in solubility (Maharaj et al., 2016). 
Maturation of intestinal drug-metabolizing enzymes and transporters 
determine age-dependent bioavailability (Fakhoury et al., 2005; Mooij 
et al., 2014). However, maturational changes are commonly 
enzyme-specific, and can be organ specific. Based on midazolam and 
1-hydroxy-midazolam disposition following oral or intravenous mid-
azolam administration, intrinsic gut wall and liver clearance were esti-
mated to be very low (0.0196 and 6.7 L/h, respectively). This results in a 
highly variable and high total oral bioavailability of 92.1% (range 67–95 
%) in preterms and 66 (range 25–85 %) in stable, critically ill children, 
compared to 30 % in adults (Brussee et al., 2018b; van Groen et al., 
2021). The exposure of 1-hydroxy-midazolam and its glucuronide was 
highest in the youngest, decreasing significantly with postnatal age (van 
Groen et al., 2021). 
Non-maturational covariates, like diet or disease characteristics also 
matter. To illustrate this, human versus formula milk affects caffeine and 
dextromethorphan metabolism (Blake et al., 2006). Similarly, critical 
illness significantly reduces (-90 %) midazolam metabolism (Brussee 
et al., 2018a). 
4.1.2. Geriatrics 
Today, the advanced age population (> 65 years) represents more 
than 20 % of the global population. About 50 % of this population suffers 
from at least three chronic diseases, resulting in a significant and chronic 
use of medications (Moore et al., 2018). Despite being the main 
end-users of drugs, geriatric patients are underrepresented in clinical 
trials due to advanced age, multimorbidity or polypharmacy (Ruiter 
et al., 2019). 
Ageing is assumed to alter the physiological characteristics of the 
GIT, thus affecting oral drug absorption. The physiology of the gastro-
intestinal lumen of older people has not been yet elucidated in detail. 
Besides alterations in gastric pH values and gastric emptying, other 
luminal characteristics have been poorly investigated or poorly under-
stood in older people and geriatric patients (Russell et al., 1993; Russell 
et al., 1994; Vertzoni et al., 2020b). Russel et al reported that the inci-
dence of subjects with an elevated gastric pH in both the fasted and the 
fed state is greater in the older people and in 10% of the older people 
who participated in that clinical study, gastric pH was also elevated in 
the fasted state (Russell et al., 1993). It has also been reported that in 
50% of the elderly subjects, gastric pH decreases more slowly than in 
young subjects after the consumption of a large meal (Russell et al., 
1993). Elevated pH in older people influences gastric emptying as it has 
been shown that gastric emptying of nutrient liquids is slower in the 
elderly with an elevated pH (Russell et al., 1994). 
Although concrete data are lacking, variability is expected to in-
crease with ageing, due to multimorbidity or polypharmacy. However, 
data can be conflicting. For example, GETs in adults vs. older people 
have been published for the fed state, but they are conflicting, and/or 
not relevant for orally administered drug dosage forms (Mojaverian 
et al., 1988; Moore et al., 1983; Stillhart et al., 2020). 
4.1.3. Sex differences 
Males and females differ in physiology, disease manifestations and 
importantly, how they respond to drugs. There are significant sex- 
specific differences in terms of drug bioavailability and PK (PK) which 
can, in turn, differentially affect drug efficacy and safety. Underlying 
reasons for sex-related variations in drug performance include obvious 
differences in physiological parameters such as body fat content and 
hormonal control (Soldin et al., 2011). Fundamental differences at the 
level of the GIT, liver and kidneys can further influence drug absorption, 
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metabolism and elimination, and consequently lead to variability in 
drug therapy and potential toxicity (Valodara and Sr, 2019). 
For example, during post-market drug surveillance it became clear 
that females were more susceptible to next-day effects following the 
administration of the sedative zolpidem as drug elimination was slower 
than in males. The FDA subsequently recommended the dose of 
immediate-release and extended-release products for females to be 
reduced from 10 to 5 mg and from 12.5 to 6.25 mg, respectively (Nor-
man et al., 2017). In addition, a number of studies have reported that 
females are at a greater risk of experiencing adverse side effects by 50 – 
70% (Bots et al., 2019). It is difficult to identify whether differences in 
drug performance and adverse effects is linked to a single PK parameter 
and governed by a single organ. Rather, such sex differences may result 
from an interplay of the complete system following oral drug adminis-
tration. Herein, we focus on drug variability directly linked to GI 
physiological differences between the sexes. 
Bioavailability of orally administered drugs depends on gastric fluid 
pH and volumes, GET and SITT, competition and/or regulation of in-
testinal transporters and drug metabolising enzymes, and the potential 
interactions of sex steroids on drug PK (Hatton et al., 2015) (Figure 13). 
In terms of the stomach, males have been reported to have higher gastric 
fluid volumes than females (Gotch et al., 1957) which may affect the 
extent of drug dissolution. Average fasted gastric pH is significantly 
higher in females (2.79 ± 0.18; n = 133) than in males (2.16 ± 0.09; 
n = 252) (p < 0.05) which may be attributed to reduced acid secretion 
and the smaller stomach size seen in females (Feldman and Barnett, 
1991). Lowered gastric acid secretion may influence drug ionisation and 
solubility of pH-sensitive drugs, thereby impairing absorption in the 
small intestine and consequently, oral drug bioavailability. 
With regards to motility, females have a significantly longer half- 
GET for solids and calorific liquids (118.0 ± 8.1 min) than in males 
(91. 4 ± 7.5 min) however, GET decreases in post-menopausal females 
(97.9 ± 7.6 min) similar to that in males (Hutson et al., 1989). Vari-
abilities in drug PK can be attributed to differences in GET; for example, 
peak plasma concentration of orally administered carbidopa was ach-
ieved 22 min later in females than in males due to longer GET (Senek 
et al., 2018). Sex differences in the oral bioavailability of a gastro-
resistant ketoprofen formulation have also been demonstrated. Males 
showed a higher Cmax/AUC than females (0.468 ± 0.094 vs 0.361 ±
0.087 h− 1) and a significantly lower tmax (3 – 5 h versus 5 – 10 h) 
respectively. Such differences were attributed to the shorter GET in 
males allowing for ketoprofen to reach the appropriate intestinal envi-
ronment for dissolution and absorption to occur more rapidly (Mag-
allanes et al., 2016). 
In terms of CTT, longer transverse and descending CTT, but shorter 
rectosigmoid transit time were observed in females than males (Nandhra 
et al., 2020). The longer GI residence time for sustained-release dosage 
forms may facilitate enhanced drug absorption in females, as demon-
strated with diltiazem which is sensitive to GI transit time (Zimmermann 
et al., 1999). This, however, may be further complicated by the regu-
lation of intestinal membrane transporters and metabolising enzymes 
located in the GI mucosa. 
CYP enzymes are responsible for the metabolism of a number of drug 
substrates of which CYP2C and 3A are most commonly expressed in the 
small intestine. In terms of sex differences in clinical drug performance, 
the oral bioavailability of verapamil (a CYP3A and P-gp substrate) was 
observed to be higher in females than males, possibly from lower hepatic 
female CYP3A4 expression (Krecic-Shepard et al., 2000; Tamargo et al., 
2017), although the differing levels of intestinal CYP3A4 and P-gp 
expression between males and females may also be responsible for this 
sex difference. Drugs may also compete for intestinal membrane trans-
porters into cells which affect the downstream metabolism or avail-
ability of the drug at its target site. For example, the OATP1B1 
transporters are responsible for the transport of oestrogens including 
oestone-3-sulfaste and oestradiol 17-beta-D-glucoronide. Statins, how-
ever, are also transported by OATPB1. As such, competitive inhibition 
can occur if multiple substrates are present. Several studies have found 
sex-specific effects of SLCO1B1 genetic variants which compromise the 
efficacy of statin treatment; female SLCO1B1 521TT subjects had a 
significantly higher Cmax and AUC of pitavastatin lactone when 
compared with male 521TT subjects (Zhou et al., 2013). 
In addition, there is an increasing body of literature evidence sup-
porting the inherent sex-specific expression of a number of uptake and 
efflux intestinal transporters (Smirnova, 2012) that elicit differential 
treatment outcomes. For example, a recent study showed that plasma 
concentrations of cimetidine, a drug substrate of the intestinal efflux 
Fig. 13. Key sex differences at the level of the GIT that impact oral drug delivery and bioavailability, (M =Male; F = Female). Adapted from (Freire et al., 2011).  
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transporter P-gp were significantly higher in females than males due to 
the innately higher expression of P-gp in the proximal small intestine of 
males (Mai et al., 2020). Adding further to the complexity in formulation 
response in males and females is the sex-specific influence of excipients. 
In the presence of the solubilising excipient polyethylene glycol (PEG) 
400, cimetidine bioavailability significantly increased, but only in 
males, not in females (Mai et al., 2020). In addition, when co-formulated 
with PEG 400, the bioavailability of ranitidine significantly increased in 
male subjects but decreased in females when orally administered with 
the same formulations (Ashiru et al., 2008). In a rat model, other sol-
ubilising excipients including PEG 2000, Cremophor RH 40, Poloxamer 
188 and Tween 80 significantly enhanced ranitidine bioavailability in 
males but not females. Span 20 was also studied: although this excipient 
was able to increase oral drug bioavailability, such effects were not 
affected by sex. Sex-specific effects may be attributed to the presence of 
a polyoxyethylated group in PEG 2000, Cremophor RH 40, Poloxamer 
188 and Tween 80, but not for Span 20 (Mai et al., 2019). 
Distinct sex differences in drug performance have been further 
demonstrated in treatments for GI syndromes. For example, alosetron, a 
5-hydroxytryptamine receptor 3 antagonist, is a drug that is effective in 
females but has low performance in males (Koch et al., 2002). At iden-
tical plasma concentrations, alosetron achieves therapeutic levels only 
in females due to the fundamental difference in serotonergic receptors in 
the colon (Viramontes et al., 2001). Alosetron, however, was withdrawn 
from the market in 2000 due to significant side effects such as ischemic 
colitis, but was reintroduced in 2002 in the US under restrictive condi-
tions of use only for females suffering from severe diarrhoea-related 
irritable bowel syndrome (Farkouh et al., 2020). 
The gut microbiota adds further to the complexity to GI physiology 
and varying drug responses in males and females. For example, L-DOPA 
undergoes increased metabolism in the presence of Helicobacter pylori 
consequently decreasing drug bioavailability. The eradication of Heli-
cobacter pylori infection, however, improved L-DOPA action and clin-
ical symptoms. The prevalence of Helicobacter pylori infection, 
however, is more prevalent in male than female individuals (Cabal et al., 
2018) and as such, may lead to differences in L-DOPA PK between the 
sexes. 
Research that aims to understand differences in drug metabolism, 
including its different clinical performance in both sexes, continues to be 
very limited. It is clear that males and females respond differently to 
drugs due to the dynamic interplay of GI physiology, drug PK itself and 
contributions from other associated organs. A single PK parameter 
cannot be considered as the only rate limiting step as this may occur in a 
drug-by-drug basis. For a better understanding of the basic mechanisms 
of sex differences, future studies should be designed with this primary 
focus in mind to determine the importance of these differences in clin-
ical management. 
4.2. Surgical conditions 
4.2.1. Post-bariatric surgery changes 
Obesity has become a major public health problem with 650 million 
adults having a body mass index (BMI) ≥ 30 kg/m2 (World Health Or-
ganization, 2016 Fact Sheet No 311). With the rising numbers of obesity, 
the prevalence of bariatric surgery is increasing as it is considered the 
most effective long-term weight loss treatment (Jakobsen et al., 2018). 
Next to sustained weight-loss, bariatric surgery can improve or lead to 
the resolution of obesity-associated comorbidities (Jakobsen et al., 
2018). However, bariatric surgery can be associated with short- and 
long-term gastrointestinal and nutritional complications (Decker et al., 
2007). The post-operative incidence of complications depends on the 
patient characteristics and the type of bariatric surgery that is performed 
(Courcoulas et al., 2020). Different bariatric procedures are available, 
but one out of three performed procedures is a Roux-en-Y Gastric Bypass 
(RYGB) (Ramos et al., 2019). The RYGB is performed by constructing a 
small gastric pouch (± 30 mL). Next, the small intestine is segmented ±
30 to 50 cm below the ligament of Treitz and the distal part is anasto-
mosed to the gastric pouch with the formation of the alimentary or 
Roux-limb. The proximal part of the divided small intestine is anasto-
mosed 75–150 cm distally through a jejunojejunal anastomosis into a 
Y-configuration (Nguyen and Varela, 2017b). The anatomical alter-
ations have a profound effect on gastrointestinal physiology including 
reduced gastric mixing capacity, increased gastric pH, accelerated 
gastric emptying, reduced surface area for absorption, reduced intestinal 
first pass metabolism and a delayed inlet of bile acids and pancreatic 
juice (Stillhart et al., 2020). Together with the solubility of a drug and 
intestinal permeability, these gastrointestinal changes determine post-
operative drug bioavailability. Subtherapeutic and toxic drug levels 
have been observed after bariatric surgery for drugs that are essential to 
treat postoperative complications or remaining obesity-associated 
complications. In the following section, we discuss the postoperative 
changes in disposition of drugs that belong to different BCS classes 
(Cder/FDA, 2017). 
Metoprolol is a commonly used cardiovascular drug that belongs to 
BCS class 1 (high solubility and high permeability). Gesquiere et al. 
investigated the disposition of an immediate and controlled release 
formulation containing 200 mg metoprolol tartrate in 14 subjects before 
and after RYGB. No statistically significant differences were observed in 
the extent of oral exposure of metoprolol before or after surgery (AUC), 
Cmax or the time to reach Cmax (tmax). However, there was a tendency 
towards an increased oral exposure of metoprolol following the intake of 
an immediate release formulation (+32.4% (95% confidence interval 
(CI): 1.36; 63.5); P=0.07) and the controlled release formulation after 
surgery (+55.9% (95% CI: 5.73; 106); P=0.30). After surgery, post-
operative weight loss might compensate for the reduced area of ab-
sorption by reducing distribution volume. In addition, the tendency of 
increased exposure might originate from the bypassed area that contains 
the highest expression of metabolizing CYP enzymes. Consequently, 
decreased presystemic biotransformation might contribute to the 
increased trend of metoprolol exposure (Gesquiere et al., 2015). 
From BCS class 2 (low solubility and high permeability), the dispo-
sition of 67 mg fenofibrate (hypolipidemic agent) and 400 mg pos-
aconazole (anti-fungal agent) was investigated in two groups of 12 
subjects before and after RYGB (Gesquiere et al., 2016). 
For fenofibrate, no significant differences were observed in any of the 
PK parameters (AUC0–48 h, Cmax, tmax). Interestingly, substantial inter- 
individual differences were observed. Two subjects showed a decrease 
of more than 25% in AUC0–48 h after surgery. In contrast, for four sub-
jects an increase of more than 25% in AUC0–48 h was observed after 
surgery. The intraluminal solubility of fenofibrate depends on bile salts 
concentration, of which the inlet is delayed due to the altered intestinal 
anatomy after RYGB (Gesquiere et al., 2016). However, a two-fold in-
crease in serum bile acid concentrations has been observed after surgery 
that could explain the comparable pre- and postoperative exposure 
(Steinert et al., 2013). In addition, a similar time to reach plasma con-
centration was observed before and after surgery. The delayed inlet of 
bile acids might be compensated by an accelerated gastric emptying, 
resulting in a similar timeframe between oral drug ingestion and bile 
acid contact before and after surgery. The variable effect of surgery on 
the extent of exposure might depend on interindividual differences in 
bile acid secretion (Gesquiere et al., 2016). 
For posaconazole, a significant decrease was observed in the extent 
of exposure (3.11 ± 0.78 μg/mL*h vs 1.81 ± 0.20 μg/mL*h; P=0.03) 
and Cmax (0.12 ± 0.04 µg/mL vs 0.06 ± 0.01 µg/mL; P=0.03) after 
surgery. The solubility of posaconazole in the stomach depends on 
gastric residence time and pH, which are both affected by the formation 
of a gastric pouch. An elevated gastric pH and accelerated gastric 
emptying might reduce the capacity and the timeframe for posaconazole 
to dissolve, resulting in lower gastric concentrations (Gesquiere et al., 
2016). For poorly soluble and weakly basic drugs, the physiological 
change in pH after gastric emptying is normally associated with a drop in 
solubility and the induction of supersaturation (Hens et al., 2016; 
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Walravens et al., 2011). After RYGB, the decreased dissolution of pos-
aconazole may limit the creation of supersaturation in the Roux-limb 
and thus result in the lower systemic exposure of posaconazole after 
RYGB. 
From BCS class 3 (high solubility and low permeability), metformin 
was selected. The disposition of 1000 mg metformin was investigated in 
16 RYGB-patients and 16 gender- and BMI-matched control subjects. 
Metformin is predominantly absorbed in the proximal small intestine 
through organic cation transporters (transcellular transport) and facili-
tated diffusion (paracellular transport), which is bypassed after RYGB. 
Contrary to expectations, a tendency towards a higher systemic expo-
sure (21 %) was observed in the RYGB-patients compared to the control 
subjects (13.7 ± 6.0 μg/mL*h vs 11.4 ± 3.6; P = 0.2). In addition, a 50% 
higher bioavailability was observed in the RYGB-patients compared to 
control subjects (41.8 ± 16.2 % vs 27.8 ± 10.4 %; P = 0.007). Potential 
mechanisms, that unravel these findings, are undiscovered. But 
considering the limited absorption window, it is possible that trans- and 
paracellular metformin absorption might change after surgery due to 
intestinal morphological and/or functional adaptation (Padwal et al., 
2011). 
Furosemide is a BCS class 4 drug (low solubility and low perme-
ability). The disposition of 40 mg furosemide was investigated in 13 
RYGB-patients and 14 controls (age-, gender-, race- and BMI-matched). 
Compared with controls, significantly higher serum levels were 
observed in RYGB patients one hour (38 ± 30 ng/mL; 347 ± 253 ng/mL; 
P = 0.01) and two hours (127 ± 116 ng/mL; 591 ± 418 ng/mL; 
P = 0.02) after oral administration. A significantly shorter time to reach 
peak plasma concentration was observed in the RYGB-patients (1.8 ±
0.3 h; 4.2 ± 1.2 h; P = 0.001). The aqueous solubility of furosemide is 
pH-dependent, with a higher solubility at an increased pH. After RYGB, 
the increased gastric pH and the accelerated gastric emptying might 
explain the higher serum furosemide concentration and faster time to 
reach the peak plasma concentration (Tandra et al., 2013). 
In conclusion, these observations emphasize the fact that the PK of a 
drug can change after RYGB. Drug absorption can increase, decrease or 
remain unaltered after surgery. To date, the available PK investigations 
in bariatric patients are limited. But the available data provides already 
some rationale for the presence of interindividual variability in drug 
bioavailability in post-bariatric patients. Interindividual differences in 
gastrointestinal physiology may explain the variability to some extent, 
but the overall degree of variability and the underlying causes are 
largely unknown. 
4.2.2. Effects of surgical resection 
The normal small bowel length is highly variable and ranges between 
285 and 1049 cm based on surgical series (Tacchino, 2015; Teitelbaum 
et al., 2013). Short bowel syndrome is generally defined as a residual 
small bowel length less than two meters, measured from the 
duodeno-jejunal flexure (Pironi et al., 2015). Surgical resections as a 
life-saving intervention during mesenteric ischemia or – often repeated – 
enterectomies in patients with IBD are the two most common conditions 
leading to short bowel syndrome. In the case the preserved intestinal 
length does not suffice to absorb sufficient fluids, electrolytes and nu-
trients to sustain life without malnutrition or growth in case of children, 
this is defined as chronic intestinal failure or type 3 intestinal failure 
(Pironi et al., 2015). However, more than just the remaining intestinal 
length, also the anatomy plays an important role. If the ileocecal valve 
and the entire colon can be salvaged, for example, a small bowel length 
of 35 cm can be sufficient to avoid the need for parenteral support. 
However, at the other end of the spectrum, in the case the entire colon is 
removed and the small bowel ends in a jejunostomy, at least 100–115 cm 
of the remaining intestine is needed to avoid parenteral nutrition, fluids 
and/or electrolytes (Messing et al., 1999). Moreover, resections of the 
small intestine also influence gastric motility. Indeed, the GET is 
accelerated in patients with short bowel syndrome, most likely because 
of the lack of a hormonal ileocolonic brake (Nightingale et al., 1993). 
Self-evidently, a reduced length of small bowel has important im-
plications for drug disposition. For example, absorption of paracetamol 
and L-thyroxine was reduced in patients with short bowel syndrome, 
both of which are absorbed distally to the duodenojejunal flexure (Stone 
et al., 1984; Ueno et al., 1995). Unfortunately, the literature on oral drug 
disposition in short bowel syndrome is limited, but it can be assumed 
that most of the (better documented) alterations in drug absorption after 
bariatric surgery (see the previous section) are similar, but most likely 
more pronounced in case of short bowel syndrome-related intestinal 
failure. One important difference between both situations is that in most 
patients with short bowel syndrome, the biliopancreatic juices will be in 
contact with the ingested luminal contents and drugs more proximally, i. 
e. after emptying from the stomach, in contrast to only in the common 
limb after gastric bypass surgery, which can change drug solubility and 
absorption (Nguyen and Varela, 2017a). Nevertheless, the absence of 
the terminal ileum in most patients with short bowel syndrome in-
terrupts the normal EHC, resulting in bile acid malabsorption and 
impaired micelle formation. This could have an important impact on 
drug oral bioavailability, due to the altered drug solubilization capacity 
of the intestinal fluids (Riethorst et al., 2018b). Massive loss of bile acids, 
combined with the short transit times will lead to steatorrhea in many 
patients, which is especially problematic for lipid-soluble drugs, e.g. 
cyclosporin and azoles. 
Nevertheless, oral drug therapy is still possible in this patient pop-
ulation, even if they are fully dependent on parenteral nutrition. Indeed, 
early case reports documented therapeutic drug concentrations with 
nortriptyline and digoxin and therapeutic anticoagulation levels with 
warfarin, with as little as 12–15 cm of jejunum remaining (McFadden 
et al., 1993). However, many patients receiving parenteral nutrition are 
also treated with intermittent doses of intravenous vitamin K which can 
sometimes explain an apparent resistance to vitamin K antagonists or 
unstable anticoagulation levels (Pironi et al., 2016). If therapeutic drug 
monitoring is possible and readily available, oral drug therapy can be 
attempted even in the case of limited small bowel length. Also for drugs 
for which monitoring is not recommended in the general population, e. 
g. the non-vitamin K oral anticoagulant drugs, therapeutic drug moni-
toring can be a useful tool in guiding oral drug therapy after surgical 
resection. Indeed, rivaroxaban and dabigatran reached lower peak levels 
in a recent study including six short bowel syndrome patients (Cheung 
et al., 2017). This is of importance since patients with short bowel 
syndrome are more likely to suffer from atrial fibrillation as a cause of 
mesenteric ischemia or to develop thromboses as a consequence of the 
indwelling central intravenous line, necessitating long-term anti-
coagulation. Subcutaneous administration of low-molecular weight 
heparins is an alternative in this situation but less convenient for the 
patients. 
If available, soluble drug formulations, including effervescent tab-
lets, buccal administration forms or liquid solutions, are preferred to 
bypass the dissolution phase and leave more time for drug absorption 
(Ward, 2010). However, oral drug solutions are often hyperosmolar and 
can stimulate luminal secretion, further increasing intestinal fluid and 
electrolyte losses (Dickerson and Melnik, 1988). In general, modified 
release formulations should be avoided in patients with short bowel 
syndrome because of the unpredictable and often incomplete release 
and absorption (Ward, 2010). An exhaustive description of the drug 
disposition of individual drugs after surgical resections, including short 
bowel syndrome, is beyond the scope of the current review, but has 
recently been covered elsewhere (Santamaria et al., 2018). 
Guidelines recommend the treatment with a double dose proton-pump 
inhibitor (PPI) in patients with short bowel syndrome, thereby reducing 
gastric acid secretion and as a consequence stomal output, especially in 
case of end-jejunostomy (Jeppesen et al., 1998; Pironi et al., 2016). 
Changing gastric acidity by a high-dose PPI will alter drug solubility and 
absorption, although no specific data are available in short bowel syn-
drome (Gubbins and Bertch, 1991; Rubbens et al., 2016). High-dose 
loperamide, codeine and sometimes octreotide are used to slow down 
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gastrointestinal motility to allow more time for nutrient, fluid and drug 
absorption, although the effect of motility-inhibitors on drug absorption 
in short bowel syndrome has not been evaluated. More recently, 
glucagon-like peptide 2 analogues such as teduglutide are used to 
improve absorption through their intestinotrophic effects, i.e. increase of 
the absorptive surface (Wauters and Vanuytsel, 2018). In clinical practice, 
an increased absorption of drugs of which the levels are monitored, 
including tacrolimus (personal experience, Tim Vanuytsel), are observed 
during the administration of glucagon-like peptide 2 analogues, but 
studies evaluating oral drug absorption in this setting are lacking. 
4.3. Chronic diseases 
4.3.1. Effect of gut function variability in chronic constipation on clinical 
drug performance 
Chronic constipation is a disorder characterised by the presence of 
alteration of bowel habit in terms of reduced frequency, increased stool 
consistency, straining, presence of feeling of incomplete evacuation 
and/or need of manual manoeuvres to complete evacuation (Bharucha 
et al., 2013). Almost everyone experiences an episode of constipation at 
some point in their life but fortunately most episodes of constipation are 
temporary. However, for some individuals the problem with con-
stipation can become chronic. Chronic constipation affects about 16% of 
the population worldwide. 
Chronic constipation is considered the result of alterations of gut 
secretory and motor function (Bharucha et al., 2013). The role of altered 
secretion is still unclear as until the recent application of the MRI to 
study in vivo in humans the intraluminal content, the only way to assess 
secretion in vivo was through invasive intraluminal sampling (Camilleri 
et al., 2017). Constipation is therefore normally classified as con-
stipation with normal or delayed colon transit and/or with defecation 
disorder (Bharucha et al., 2013). In large studies conducted in tertiary 
care centres it has been demonstrated that about 20% of patients with 
chronic constipation present with slow transit (Camilleri et al., 2008; 
Simren et al., 2019). Patients with chronic constipation can also manifest 
alterations of the transit time of other parts of the gut. Previous studies 
have reported that the presence of delayed gastric emptying and/or 
small bowel transit time is frequent in patients with chronic constipation 
(Kuo et al., 2011; Shahid et al., 2012). 
It should be noted that gut transit is an indirect measure of motility. 
It has indeed become clear that the same colonic transit time can result 
from quite different colonic motor patterns. Studies conducted by means 
of the magnetic capsule have demonstrated that in healthy individuals, 
same colonic transit time could be the result of the capsule remaining for 
about 21 hours in the right colon and then travelling the entire colon to 
be expelled by the rectum by a single high amplitude propagating 
contraction or alternatively resulting from the capsule slowly transiting 
the entire colon during the same amount of time (Mark et al., 2019). 
Preliminary data in patients with slow transit constipation suggest that 
the same entity of delayed colonic transit can be the result of reduced 
propulsive motor activity or from an increase of non-propulsive motor 
activity (Corsetti et al., 2016). This different motor response of the colon 
in health and disease is likely to affect the clinical performance of the 
drug. Longer retention of a drug in the right colon where normally the 
intraluminal content is expected to be different from other regions of the 
colon, in terms of viscosity, pH, bile acids, microbiota is expected to 
influence its bioavailability (Koziolek et al., 2019). 
The situation is made more complex by the fact that different tech-
niques have been applied in the literature to measure gut transit and 
even for what is considered the gold standard (scintigraphy) there is no 
standardization across centres (Corsetti et al., 2019). This of course 
needs to be considered when evaluating or performing studies assessing 
the variability of gut function. 
In the literature no studies have formally evaluated the influence of 
chronic constipation and of its different subtypes (normal or delayed 
colon transit and/or with defecation disorder) on drug clinical 
performance. However, some information can be collected by the 
studies in Parkinson’s disease where the alteration of gut transit has 
been reported to affect bioavailability of drugs used to treat this con-
dition (Mukherjee et al., 2016). In these patients, chronic constipation 
and alteration of gut function have been demonstrated to precede 
neurological symptoms (Leclair-Visonneau et al., 2020). A systematic 
review has estimated the prevalence of delayed gastric emptying is be-
tween 70 % and 100 % in patients with Parkinson’s disease (Heetun and 
Quigley, 2012). Recent studies applying the magnetic capsule in a small 
group of patients with Parkinson’s have found that 79 % percent of 
Parkinson’s disease patients displayed prolonged colonic transit time 
(Knudsen et al., 2017). In these patients a significant relationship has 
been found between L-DOPA PK and gastric emptying (Marrinan et al., 
2014). 
All these data suggest that future studies should clarify whether the 
alterations of gut function associated with chronic constipation influ-
ence the clinical performance of drugs. These studies should be con-
ducted standardising the technique to study gut function and 
considering the factors that have been already demonstrated to affect 
gut function in health. Ideally, a non-invasive technique allowing the 
simultaneous evaluation of the transit of the different part of the gut 
(stomach, small bowel and colon), such as scintigraphy or MRI would be 
preferable. In the case of drugs that are expected to behave like undig-
estible food techniques such as the wireless capsule or the magnetic 
capsule would add the advantage of evaluating the retention time in 
specific areas of the gut. 
4.3.2. Effects of small intestinal motility disorders on clinical performance 
of drugs 
For most drugs, the principal site of absorption is the proximal small 
intestine. Absorption primarily depends on the overall absorptive ca-
pacity, but drug absorption is also influenced by small intestinal 
motility. In humans, SITT is reasonably constant (for the case of chronic 
constipation, see section 4.3.1): at around three hours for a drug 
formulation (or for a meal) to pass from the stomach to the ileo-caecal 
junction (Davis et al., 1986). 
Consequently, the bioavailability of a drug, which is largely or 
exclusively absorbed from the proximal small intestine, will be affected 
by factors that change GI transit. Increases in small intestinal transit are 
one of the key factors impacting drug absorption, as has been elegantly 
shown using mannitol for cimetidine, a polar drug that is almost 
exclusively absorbed from the small intestine (Adkin et al., 1995b). Such 
phenomena can also explain the impact of certain laxatives on drug 
absorption, although reports on this subject are scarce (Altree and Gal-
letly, 2013). 
Drugs most affected by changes to small intestinal transit are 
generally those with narrow absorption windows in the small intestine, 
the most important ones being acyclovir, atenolol, bisphosphonates, 
captopril, cimetidine, furosemide, metformin, gabapentin, L-DOPA, 
baclofen, ciprofloxacin and verapamil. 
Several pathological conditions of the GIT are known to affect SITT, 
see Table 6. It is noteworthy, however, that drug absorption has generally 
not been systematically assessed in these conditions as other mechanisms 
Table 6 
Pathological conditions of the GIT known to affect SITT.  
Disorders resulting in increased small 
intestinal transit 
Disorders resulting in decreased 
intestinal transit 
Malabsorption syndromes (osmotic effect) Chronic intestinal pseudoobstruction 
(CIPO) 
Infectious enterocolitis Crohn’s disease 
(active) 
Systemic sclerosis 
Radiation enteritis Postoperative ileus 
Hyperthyroidism Spinal cord injury 
Neuroendocrine tumor Hypothyroidism  
Parkinson’s disease  
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can also influence bioavailability in these disorders. For lactose intoler-
ance and celiac disease (both causes for malabsorption syndromes), 
Crohn’s disease, Parkinson’s disease and infectious enterocolitis, we refer 
here to a recent UNGAP review specifically discussing these conditions 
(Stillhart et al., 2020). The impact of spinal cord injury on drug PK is 
extensively discussed elsewhere (Mestre et al., 2011). 
A particular case of alteration in small intestinal motility is post-
operative ileus, a condition seen often in clinical practice. Postoperative 
ileus is an iatrogenic condition that occurs following abdominal surgery, 
characterized by transient cessation of coordinated propulsive motility 
(Boeckxstaens and de Jonge, 2009). 
The inability to restore normal intestinal motility in the post-
operative phase will also impact oral drug bioavailability. In these 
clinical situations, it is important to realize that the motility of the 
proximal small intestine is perturbed in the immediate postoperative 
phase and that normal motor patterns including phasic motor activity 
only normalizes after approximately 50–70 hours. (Benson et al., 1994) 
As for the impact of these changes on drug bioavailability, a study 
examining differences between pre- and postoperative PK of paraceta-
mol administered to the duodenum found peak plasma concentration 
from the small bowel to be decreased postoperatively but the overall 
amount of paracetamol absorbed over time was unaffected (Kennedy 
and van Rij, 2006). One of the postulated mechanisms for the observed 
effect was related to an alteration in the spread of the paracetamol 
mixture throughout the GIT or reflux back into the stomach. The ques-
tion still remains to which extent postoperative motility disorders 
contribute to drug bioavailability and whether this is also drug-specific. 
4.3.3. Patients on proton pump inhibitors 
PPIs inhibit the H+/K+-ATPase in gastric parietal cells, which brings 
about a reduction of acid secretion and hence an increase in gastric pH. 
One direct effect of PPIs is the increase of the gastric pH (hypochlo-
rhydria) which might reduce the absorption of weakly basic drugs that 
are more soluble in acidic environments. Also, PPIs cause reduced 
gastric osmolality, surface tension, and reduced buffer capacity and 
these factors are major modifiers of drug absorption. It is of note that the 
increase in pH also affects the first portion of the small intestine (Litou 
et al., 2016) and therefore intestinal drug absorption is also modified by 
PPIs. Also, PPIs influence drug absorption because of their effect in the 
CYP system affecting the intestinal first-pass metabolism (Blume et al., 
2006). 
PPIs are considered as drugs with a good safety profile, because they 
provoke mild and infrequent adverse drugs events, and are widely used 
because of their low cost and, in most countries, their availability over 
the counter. PPIs are used as a single dose or as a short-term treatment, 
to treat unspecific gastrointestinal symptoms. Besides, these drugs are 
frequently used in the long-term for diseases such as gastroesophageal 
reflux, treatment of peptic ulcer, or prevention of gastrointestinal 
adverse events during NSAID therapy. It is in the context of chronic 
treatment where the effect of PPIs in drug absorption becomes of 
particular relevance. 
The influence of PPIs in anticancer therapy is of special concern 
because many recently approved oral anticancer drugs have pH- 
dependent solubility. Of particular clinical relevance is that PPIs nega-
tively affect the absorption of oral tyrosine kinase inhibitors (TKIs). 
Interactions of PPIs with several TKIs such as dacomitinib, dasatinib, 
erlotinib, gefitinib, ibrutinib, neratinib, osimertinib, pazopanib, or 
ponatinib have been described. PK exposure to TKIs was reduced upon 
co-administration of PPIs such as omeprazole, lansoprazole, esomepra-
zole, and rabeprazole, in all cases due to the increased gastric pH. For 
example, the maximum plasma concentration (Cmax) and AUC of dasa-
tinib decreased by 63 % and 61 %, respectively, even when administered 
10 h after a single dose of PPI (FDA 2011). Besides TKIs, the area under 
the curve for other kinase inhibitors such as acalabrutinib, ceritinib, 
palbociclib, pictilisib, and ribociclib is also reduced when 
co-administered with PPIs. For recent reviews, see (Gay et al., 2017; 
Keller et al., 2018; van Leeuwen et al., 2017). The co-administration of 
acidic drinks (e.g. cola drinks), can be expected to increase significantly 
the bioavailability of these kinase inhibitors in patients receiving PPIs. 
So far, this has been shown for the combined use of erlotinib plus eso-
meprazole (van Leeuwen et al., 2016). Also, re-acidification of the 
gastric pH with betaine hydrochloride restores absorption, as it has been 
shown in the absorption of dasatinib in patients with hypochlorhydria 
induced with rabeprazole (Yago et al., 2014). The absorption of oral 
anticancer drugs classified as Hedgehog signaling inhibitors such as 
glasdegib and sonidegib is modestly affected by PPIs such as rabeprazole 
or esomeprazole (Giri et al., 2017; Zhou et al., 2016) Another oral 
anticancer drug that is affected by co-administration of PPIs is capeci-
tabine (Chu et al., 2017), and a decrease in progression-free survival has 
been reported for patients receiving capecitabine and PPIs (Wong et al., 
2019). Therefore, the effects of acid reducing agents on cancer thera-
peutics are challenging not only for oncologists but also for pharma-
ceutical companies developing new drugs and regulators that aim to 
achieve safe and efficacious products for patients (Smelick et al., 2013). 
Another group of drugs affected by PPIs, also due to changes in 
gastric and intestinal pH, are antivirals such as atazanavir or glecapre-
vir. Atazanavir is an antiretroviral used in the treatment of HIV and 
glecaprevir is used in the treatment of Hepatitis C virus. Co- 
administration of PPIs cause a significant decrease in the bioavail-
ability of these drugs (Faber et al., 2017; Flamm et al., 2019), and it is 
widely accepted that the use of PPIs should be carefully considered in 
patients receiving these antivirals. 
The absorption of oral antifungal drugs such as itraconazole, keto-
conazole, or posaconazole is also affected by PPIs, which cause a 
decrease in their bioavailability due to the pH-dependent solubility of 
these drugs (Abuhelwa et al., 2019; Dolton et al., 2014; Ogawa and 
Echizen, 2010; Walravens et al., 2011). 
Regarding hormones, PPIs affect the absorption of ulipristal, a se-
lective progesterone receptor modulator that has a pH-dependent solu-
bility. Co-administration with esomeprazole causes a significant 
decrease in ulipristal plasma concentrations (Pohl et al., 2013). Also, the 
dissolution of levothyroxine tablets is pH-dependent and it has been 
shown that PPIs impair absorption and decrease exposure to this syn-
thetic hormone (Vita et al., 2014). 
Another drug that has its PK profile affected due to the effect of PPIs 
is mycophenolic acid, an immunosuppressant drug, and an increase in 
the risk of organ rejection has been reported in some patients when 
receiving concomitantly PPIs (Knorr et al., 2014). 
Clinically relevant interaction of PPIs with cardiovascular drugs lies 
in the fact that the absorption and the bioavailability of the cardiotonic 
drug digoxin, and the calcium channel blocker nifedipine, is increased 
when gastric pH is increased (Fashner and Gitu, 2013). 
Besides drugs, PPIs modify the absorption of iron, magnesium, and 
calcium. Dietary iron absorption is affected by PPIs because iron ab-
sorption is more efficient in the reduced form (Fe2+) than in the dietary 
form (Fe3+), and this reduction is facilitated by the acidic gastric fluids. 
It has been reported an increased risk of anemia, or of having altered 
anemia-related analytical values in PPI users as compared to non-PPI 
users (Sarzynski et al., 2011). Magnesium absorption is also affected 
by PPIs, due to reduced magnesium active transport and reduced ab-
sorption due to increased pH. This is especially relevant in elderly pa-
tients and patients with polypharmacy (Yucel et al., 2016). Calcium 
absorption is reduced too in PPI users as a consequence of hypochlo-
rhydria, and increased risk of fractures has been reported in patients 
receiving PPIs (Kim et al., 2020). Vitamin B12 deficiency has been re-
ported to occur in PPI users and the proposed mechanism to explain such 
association is a reduction of protein-bound vitamin B12 absorption due 
to a decrease of gastric proteolytic digestion, which is affected by gastric 
pH (Eusebi et al., 2017). 
PPIs can also alter drug absorption and exposure indirectly because 
they alter the gastric microbiome. After one year of treatment with PPIs, 
the number of colony-forming units in gastric juices and in the 
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duodenum grows dramatically (Fisher and Fisher, 2017), and persistent 
changes toward a less healthy gut microbiome are observed in PPI users 
(Imhann et al., 2016) (for more information on the role of the gut 
microbiome in drug PK, see the relevant section in this manuscript). 
Also, PPIs reduce steatorrea after treatment with pancreatic enzymes 
(Proesmans and De Boeck, 2003). In sum, PPIs cause frequent and 
clinically relevant drug interactions due to hypochlorhydria, which take 
special importance in elderly patients, in patients with susceptibility or 
additional risk factors for bone fractures or gastrointestinal infections, 
and patients under polypharmacy. 
4.3.4. Effects of anorexia and cachexia on drug PK 
Anorexia is defined as a loss of normal appetite. Anorexia can have 
different causes, including eating disorders such as anorexia nervosa. A 
related term is cachexia, which refers to the situation when anorexia is 
associated with nutritional deficiencies and involuntary weight loss, as a 
result of an underlying chronic disease. Cachexia is characterized by 
progressive nutritional changes, weakness, and wasting, is often debil-
itating and potentially life-threatening over a lengthy period (Bruera, 
1997). It is a hypercatabolic state that is defined by an accelerated loss of 
skeletal muscle in the context of a chronic inflammatory response. 
Anorexia and cachexia are most frequently seen in the later stages of the 
acquired immunodeficiency syndrome (AIDS), dementia, cancer, heart 
failure and renal failure. Cachexia-induced changes in bodily functions 
may alter the PK of various drugs. These changes include the following 
mechanisms, according to an absorption, distribution, metabolism and 
excretion (ADME) concept (see Table 7 for a summary). Changes in the 
gut wall such as increased bowel wall thickness (due to edema and 
increased collagen deposition), increased intestinal permeability, 
changes in intestinal motility, decreased splanchnic perfusion and 
impaired function of transport proteins are associated with weight loss 
regardless of the underlying chronic disease (Barry, 1974). Higher in-
testinal permeability can also affect drug bioavailability, which has been 
discussed earlier in this paper (2.2). 
As for specific changes in patients with cachexia, a limited number of 
studies (Mouly et al., 2000; Trout et al., 2004) investigated the impact of 
diarrhea in combination with weight loss in patients with HIV-infected 
patients. Increased intestinal permeability is a key factor in drug ab-
sorption in these patients (Keating et al., 1995). It was observed that 
these patients showed higher intestinal absorption of ganciclovir and 
saquinavir as demonstrated by higher AUC (area under 
concentration-time curve) and oral clearance. On the contrary, lower 
bioavailability was observed in AIDS-associated diarrhea and wasting 
for stavudine and didanosine (Brantley et al., 2003). This discrepancy is 
probably explained by the difference in PK properties of the specific 
drugs: drugs with otherwise low bioavailability (ganciclovir, saquinavir) 
have an increased absorption due to higher intestinal permeability; 
drugs with otherwise good intestinal absorption (stavudine, didanosine) 
are more influenced by faster elimination of the drug from the GIT, 
which results in lower bioavailability. Therefore, it was suggested that 
doses of low bioavailability drugs should be lowered and doses of drugs 
with high bioavailability should be increased in cachectic patients with 
wasting and diarrhea (Trobec et al., 2013). It remains to be established 
whether such recommendations can be extrapolated to other pop-
ulations affected by cachexia. 
Due to the fact that we have an incomplete understanding how 
cachexia can impact oral and subcutaneous drug bioavailability and 
drug metabolism, in current clinical practice, the medication dose is 
usually guided by experience and clinical effect, resulting in adaptation 
of a universal starting dose rather than defining a personalized dose 
beforehand based on solid PK characteristics (Franken et al., 2016). To 
overcome these shortcomings, initiatives have been taken to predict PK 
profiles and the effect of intrinsic and extrinsic factors using 
population-based PBPK modeling approach in an oncology population 
(Cheeti et al., 2013). Until such prediction models can be fine-tuned, 
alternative routes of drug administration should be preferred when 
there is an evident discrepancy between administered dose and clinical 
effect, or when this situation is to be expected a priori based on the 
clinical condition of the patients. Nonetheless, as most drugs for chronic 
diseases are administered orally, studies focusing on drug absorption in 
cachexia are highly necessary to optimize PK predictive models. 
Obtaining such data can however easily run into practical issues of 
execution due to ethical considerations, particularly in the terminally ill. 
Modeling studies using limited sampling strategies may therefore pro-
vide a solution and may eventually lead to individualized dosing 
guidelines (Franken et al., 2016). 
Of note is that other causes of anorexia, such as anorexia nervosa, are 
not associated with a substantial systemic inflammatory reaction 
(Dalton et al., 2018) and therefore impact drug bioavailability to a 
different extent. In fact, a study investigating the bioavailability of oral 
ergocalciferol showed that bioavailability was similar in young women 
with anorexia nervosa with severe malnutrition compared to 
healthy-weighted controls (Divasta et al., 2011). 
5. Summary and future outlook 
Variability of drug exposure after oral administration has been 
known as long as pharmacokinetics itself, yet it still poses a formidable 
challenge in modern drug development. While the parameters influ-
encing oral drug absorption and PK are as diverse as any aspect of 
human physiology, the issue is further complicated by the various 
enabling formulation technologies available. The purpose of the current 
paper was to facilitate the exploration of this difficult problem by 
collating literature data on the various aspects of variability and 
examining the evidence for impact on oral drug absorption and/or PK 
(Table 8). 
While GI physiology is currently studied relatively well in the 
healthy adult, this is not the case for pediatric, geriatric and various 
other patient populations, which hinders any attempt to understand the 
reasons behind drug absorption differences in case studies. Hence, 
considerable future efforts should be dedicated to studying these pop-
ulations that are frequently underrepresented (if present at all) in the 
academic and industry-driven clinical trials. 
At the same time, clinical evidence for the impact of well- 
characterized GIT variables on drug absorption is also scarce. Hence, 
only a handful of factors are relatively well characterized, and their 
impact on variable drug absorption has been illustrated by clinical 
Table 7 
Mechanisms by which oral drug disposition can be influenced by cachexia.  
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studies: intestinal fluid volume, drug formulation type, PPIs, age and sex 
differences. Most of the other factors considered either require more in- 
depth characterization, or dedicated clinical studies, in order to clarify 
the implications on drug absorption. 
Looking ahead, the opportunity to minimize variability is probably 
only truly possible in a clinical academic setting. Do we therefore have 
to live with much greater variability in the patient setting? To control 
the release of oral drugs via robust physicochemical mechanisms, we 
will need to quantify the impact of genetic influences, societal factors 
and physiological variables (e.g. gastrointestinal transit), which in turn 
are affected by diet, energy output and drug effects. Thus, understanding 
our patient is key and variability is multi-factorial. 
So how could the industry respond to this challenge, and to the de-
mand for personalized medicine? Ultimately, we should aim to accu-
rately model the ranges of drug exposure and peak concentrations that 
will be experienced by patients. This will then assure that our medicines 
possess an efficacy and safety profile tailored to the heterogenous pop-
ulation that we seek to treat. In that respect, society has to make choices, 
because more information about individuals and specifically those who 
need to be treated, needs to be securely shared across healthcare 
providers. 
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